Literatur

NVL Chronische Herzinsuffizienz, 3. Auflage, 2019. Version 2

1. Europarat, Verbindung der Schweizer Ärztinnen und Ärzte, Ärztliche Zentralstelle Qualitätssicherung (ÄZQ), et al. Entwicklung einer Methodik für die Ausarbeitung von Leitlinien für optimale medizinische Praxis. Empfehlung Rec (2001)13 des Europarates am 10. Oktober 2001 und Erläuterndes Memorandum. Deutschsprachige Ausgabe. Z Arztl. Fortbild. Qualitatssich. 2002; 96(Suppl III):3–60.

2. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV). Beurteilungskriterien für Leitlinien in der medizinischen Versorgung - Beschlüsse der Vorstände der Bundesärztekammer und Kassenärztlicher Bundesvereinigung, Juni 1997. Dtsch Arztebl 1997; 94(33):A-2154-5.

3. Qaseem A, Forland F, Macbeth F, et al. Guidelines International Network: Toward International Standards for Clinical Practice Guidelines. Ann Intern Med 2012; 156(7):525–31. http://www.ncbi.nlm.nih.gov/pubmed/22473437.

4. Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Deutsches Instrument zur methodischen Leitlinien-Bewertung (DELBI). Fassung 2005/2006. Z Arztl Fortbild Qualitatssich 2005; 99(8):468–519.

5. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Das AWMF-Regelwerk Leitlinien. München: Zuckschwerdt; 2012. http://www.awmf.org/leitlinien/awmf-regelwerk.html.

6. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Programm für Nationale VersorgungsLeitlinien - Methodenreport, 5. Auflage. Version 1. 2017 [cited: 2019-09-05]. DOI: 10.6101/AZQ/000169. http://doi.org/10.6101/AZQ/000169.

7. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz - Leitlinienreport, 3. Auflage. Version 2. 2019 [cited: 2020-06-09]. DOI: 10.6101/AZQ/000468. http://doi.org/10.6101/AZQ/000468.

8. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328(7454):1490–7. http://www.ncbi.nlm.nih.gov/pubmed/15205295.

9. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336(7650):924–6. http://www.ncbi.nlm.nih.gov/pubmed/18436948.

10. Dunham RB. Nominal Group Technique: A Users’ guide. Madison: Wisconsin School of Business; 1998.

11. Stinner B, Bauhofer A, Sitter H, et al. Nominaler Gruppenprozess als Konsensusinstrument zur Einschränkung der Therapieheterogenität in einer komplexen „outcome“-Studie. Intensivmed Notfallmed 2000; 37 Suppl. 2:30.

12. Murphy MK, Black NA, Lamping DL, et al. Consensus development methods, and their use in clinical guideline development. Nature 1998; 2(3):i-88. http://www.ncbi.nlm.nih.gov/pubmed/9561895.

13. Ponikowski P, Anker S, Voors AA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2016: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology. Developed with the special contribution Heart Failure Association (HFA) of the ESC. 2016 [cited: 2019-10-01]. http://www.escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/Acute-and-Chronic-Heart-Failure.

14. Lip GY, Gibbs CR, Beevers DG. ABC of heart failure: Aetiology. Br Med J 2000; 320(7227):104–7. http://www.ncbi.nlm.nih.gov/pubmed/10625270.

15. Page RL, O’Bryant CL, Cheng D, et al. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. Circulation 2016; 134(6):e32-e69. DOI: 10.1161/CIR.0000000000000426. http://www.ncbi.nlm.nih.gov/pubmed/27400984.

16. Brozena SC, Jessup M. The new staging system for heart failure. What every primary care physician should know. Geriatrics 2003; 58(6):31–6. http://www.ncbi.nlm.nih.gov/pubmed/12813870.

17. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62(16):e147-e239. DOI: 10.1016/j.jacc.2013.05.019. http://www.ncbi.nlm.nih.gov/pubmed/23747642.

18. Alba AC, Rao V, Ivanov J, et al. Usefulness of the INTERMACS scale to predict outcomes after mechanical assist device implantation. J Heart Lung Transplant 2009; 28(8):827–33. DOI: 10.1016/j.healun.2009.04.033. http://www.ncbi.nlm.nih.gov/pubmed/19632580.

19. Klauber J, Günster C, Gerste B, editors. Versorgungs-Report 2015/2016: Kinder und Jugendliche. Stuttgart: Schattauer; 2016.

20. Tiller D, Russ M, Greiser KH, et al. Prevalence of symptomatic heart failure with reduced and with normal ejection fraction in an elderly general population-the CARLA study. PLoS. One. 2013; 8(3):e59225. DOI: 10.1371/journal.pone.0059225. http://www.ncbi.nlm.nih.gov/pubmed/23555000.

21. Ohlmeier C, Mikolajczyk R, Frick J, et al. Incidence, prevalence and 1-year all-cause mortality of heart failure in Germany: A study based on electronic healthcare data of more than six million persons. Clin Res Cardiol 2015; 104(8):688–96. DOI: 10.1007/s00392-015-0841-4. http://www.ncbi.nlm.nih.gov/pubmed/25777937.

22. Stork S, Handrock R, Jacob J, et al. Epidemiology of heart failure in Germany: A retrospective database study. Clin Res Cardiol 2017; 106(11):913–22. DOI: 10.1007/s00392-017-1137-7. http://www.ncbi.nlm.nih.gov/pubmed/28748265.

23. Statistisches Bundesamt (Destatis). Die 10 häufigsten Todesursachen. Sterbefälle insgesamt nach der ICD-10 im Jahr 2015. Herzinsuffizienz (Herzschwäche, Herzmuskelschwäche). 2015 [cited: 2018-07-06]. http://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Gesundheit/Todesursachen/Tabellen/HaeufigsteTodesursachen.html.

24. Kaduszkiewicz H, Gerste B, Eisele M, et al. Herzinsuffizienz: Epidemiologie und Versorgung. In: Klauber J, Günster C, Gerste B, editors. Versorgungs-Report 2013/14: Depression. Stuttgart: Schattauer; 2014, p. 209–229.

25. Störk S, Hense HW, Zentgraf C, et al. Pharmacotherapy according to treatment guidelines is associated with lower mortality in a community-based sample of patients with chronic heart failure. A prospective cohort study. Eur J Heart Fail 2008; 10(12):1236–45. http://www.ncbi.nlm.nih.gov/pubmed/18996739.

26. Vasan RS, Xanthakis V, Lyass A, et al. Epidemiology of Left Ventricular Systolic Dysfunction and Heart Failure in the Framingham Study: An Echocardiographic Study Over 3 Decades. JACC. Cardiovasc Imaging 2018; 11(1):1–11. DOI: 10.1016/j.jcmg.2017.08.007. http://www.ncbi.nlm.nih.gov/pubmed/28917679.

27. Meinertz T, Hamm C, Schlensak C, et al. Deutscher Herzbericht 2017: 29. Sektorenübergreifende Versorgungsanalyse zur Kardiologie, Herzchirurgie und Kinderherzmedizin in Deutschland. Frankfurt: Deutsche Herzstiftung; 2017.

28. Gerste B, Günster C. Diagnosehäufigkeit und Inanspruchnahme von Gesundheitsleistungen. In: Klauber J, Günster C, Gerste B, editors. Versorgungs-Report 2013/14: Depression. Stuttgart: Schattauer; 2014, p. 257–308.

29. Swindle JP, Chan WW, Waltman JK, et al. Evaluation of mortality and readmissions following hospitalization with heart failure. Curr Med Res Opin 2016:1–11. DOI: 10.1080/03007995.2016.1205972. http://www.ncbi.nlm.nih.gov/pubmed/27348501.

30. Arundel C, Lam PH, Khosla R, et al. Association of 30-Day All-Cause Readmission with Long-Term Outcomes in Hospitalized Older Medicare Beneficiaries with Heart Failure. Am J Med 2016; 129(11):1178–84. DOI: 10.1016/j.amjmed.2016.06.018. http://www.ncbi.nlm.nih.gov/pubmed/27401949.

31. Pocock SJ, Ariti CA, McMurray JJ, et al. Predicting survival in heart failure: A risk score based on 39 372 patients from 30 studies. Eur Heart J 2013; 34(19):1404–13. DOI: 10.1093/eurheartj/ehs337. http://www.ncbi.nlm.nih.gov/pubmed/23095984.

32. Ouwerkerk W, Voors AA, Zwinderman AH. Factors influencing the predictive power of models for predicting mortality and/or heart failure hospitalization in patients with heart failure. JACC Heart Fail 2014; 2(5):429–36. DOI: 10.1016/j.jchf.2014.04.006. http://www.ncbi.nlm.nih.gov/pubmed/25194294.

33. Rahimi K, Bennett D, Conrad N, et al. Risk prediction in patients with heart failure: A systematic review and analysis. JACC Heart Fail 2014; 2(5):440–6. DOI: 10.1016/j.jchf.2014.04.008. http://www.ncbi.nlm.nih.gov/pubmed/25194291.

34. Ezekowitz JA, O‘Meara E, McDonald MA, et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Can J Cardiol 2017; 33(11):1342–433. DOI: 10.1016/j.cjca.2017.08.022. http://www.ncbi.nlm.nih.gov/pubmed/29111106.

35. Mant J, Doust J, Roalfe A, et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess 2009; 13(32):1-207, iii. http://www.ncbi.nlm.nih.gov/pubmed/19586584.

36. Kelder JC, Cramer MJ, van Wijngaarden J, et al. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation 2011; 124(25):2865–73. DOI: 10.1161/CIRCULATIONAHA.111.019216. http://www.ncbi.nlm.nih.gov/pubmed/22104551.

37. National Institute for Health and Care Excellence (NICE). Acute heart failure: diagnosing and managing acute heart failure in adults. 2014 (NICE Clinical Guideline; 187) [cited: 2018-11-09]. http://www.nice.org.uk/guidance/cg187/resources/acute-heart-failure-diagnosis-and-management-pdf-35109817738693.

38. Scottish Intercollegiate Guidelines Network (SIGN). Management of chronic heart failure. Edinburgh: SIGN; 2016 (SIGN Publications; 147). http://www.sign.ac.uk/assets/sign147.pdf.

39. National Institute for Health and Care Excellence (NICE). Chronic heart failure in adults. Diagnosis and management. 2018 (NICE Clinical Guideline; 106) [cited: 2018-10-09]. http://www.nice.org.uk/guidance/ng106/resources/chronic-heart-failure-in-adults-diagnosis-and-management-pdf-66141541311685.

40. Taylor KS, Verbakel JY, Feakins BG, et al. Diagnostic accuracy of point-of-care natriuretic peptide testing for chronic heart failure in ambulatory care: Systematic review and meta-analysis. BMJ (Clinical research ed.) 2018; 361:k1450. http://www.ncbi.nlm.nih.gov/pubmed/29785952.

41. Balion C, Don-Wauchope A, Hill S, et al. Use of Natriuretic Peptide Measurement in the Management of Heart Failure. 2013 (Comparative Effectiveness Reviews; 126) [cited: 2018-10-10]. http://effectivehealthcare.ahrq.gov/sites/default/files/pdf/heart-failure-natriuretic-peptide_research.pdf.

42. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017; 136(6):e137-e161. DOI: 10.1161/CIR.0000000000000509. http://www.ncbi.nlm.nih.gov/pubmed/28455343.

43. National Institute for Health and Care Excellence (NICE). Surveillance programme Surveillance proposal consultation document Acute heart failure NICE guideline CG187 – 2017 surveillance review. 2017 (NICE Clinical Guideline; 187) [cited: 2018-11-09].

44. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016; 29(4):277–314. DOI: 10.1016/j.echo.2016.01.011. http://www.ncbi.nlm.nih.gov/pubmed/27037982.

45. Hoffmann R. Positionspapier zu Qualitätsstandards in der Echokardiographie. Z Kardiol 2004; 93(12):975–86. http://www.ncbi.nlm.nih.gov/pubmed/15599574.

46. Nixdorff U, Buck T, Engberding R, et al. Positionspapier zur Qualifikation und Zertifizierung von Untersuchern in der Echokardiographie. Clin Res Cardiol. Suppl 2006; 1(S2):96–102.

47. Voelker W. Strukturierter Datensatz zur Befunddokumentation in der Echokardiographie - Version 2004. Z Kardiol 2004; 93(12):987–1004. http://www.ncbi.nlm.nih.gov/pubmed/15599575.

48. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28(1):1-39.e14. DOI: 10.1016/j.echo.2014.10.003. http://www.ncbi.nlm.nih.gov/pubmed/25559473.

49. Galderisi M, Cosyns B, Edvardsen T, et al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: An expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2017; 18(12):1301–10. DOI: 10.1093/ehjci/jex244. http://www.ncbi.nlm.nih.gov/pubmed/29045589.

50. Fuat A, Hungin AP, Murphy JJ. Barriers to accurate diagnosis and effective management of heart failure in primary care: Qualitative study. BMJ 2003; 326(7382):196. http://www.ncbi.nlm.nih.gov/pubmed/12543836.

51. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische KHK - Langfassung, 5. Auflage. Version 1. 2019 [cited: 2019-04-11]. DOI: 10.6101/AZQ/000419. http://doi.org/10.6101/AZQ/000419.

52. Albus C, Waller C, Fritzsche K, et al. Bedeutung von psychosozialen Faktoren in der Kardiologie – Update 2018: Positionspapier der Deutschen Gesellschaft für Kardiologie. Der Kardiologe 2018; 131(4):339. DOI: 10.1007/s12181-018-0271-4.

53. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 1990; 16(3):199–208. http://www.ncbi.nlm.nih.gov/pubmed/10109801.

54. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30(6):473–83. http://www.ncbi.nlm.nih.gov/pubmed/1593914.

55. Morfeld M, Kirchberger I, Bullinger M. SF-36. Fragebogen zum Gesundheitszustand. 2nd ed. Göttingen: Hogrefe; 2011.

56. Bullinger M, Kirchberger I. SF-36. Fragebogen zum Gesundheitszustand. Handanweisung. Göttingen: Hogrefe; 1998.

57. Ware JJ, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34(3):220–33. http://www.ncbi.nlm.nih.gov/pubmed/8628042.

58. Siegrist J, Broer M, Junge A. Profil der Lebensqualität chronisch Kranker - Manual. Beltz Test. Göttingen: Beltz; 1996.

59. Höfer S, Schmid JP, Frick M, et al. Psychometric properties of the MacNew heart disease health-related quality of life instrument in patients with heart failure. J Eval. Clin Pract. 2008; 14(4):500–6. http://www.ncbi.nlm.nih.gov/pubmed/18462292.

60. van Weel C, König-Zahn C, Touw-Otten FWMM. Measuring functional health status with the COOP/WONCA charts: A manual. 2nd ed. Groningen: Noordelijke Centrum voor Gezondheidsvraagstukken; 2012.

61. Faller H, Steinbuchel T, Schowalter M, et al. Der Kansas City Cardiomyopathy Questionnaire (KCCQ) - ein neues krankheitsspezifisches Messinstrument zur Erfassung der Lebensqualität bei chronischer Herzinsuffizienz - Psychometrische Prüfung der deutschen Version. Psychother. Psychosom. Med Psychol. 2005; 55(3-4):200–8. http://www.ncbi.nlm.nih.gov/pubmed/15800814.

62. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J 1992; 124(4):1017–25. http://www.ncbi.nlm.nih.gov/pubmed/1529875.

63. Ghosh RK, Ball S, Prasad V, et al. Depression in heart failure: Intricate relationship, pathophysiology and most updated evidence of interventions from recent clinical studies. Int J Cardiol 2016; 224:170–7. DOI: 10.1016/j.ijcard.2016.09.063. http://www.ncbi.nlm.nih.gov/pubmed/27657469.

64. Juenger J, Schellberg D, Kraemer S, et al. Health related quality of life in patients with congestive heart failure: Comparison with other chronic diseases and relation to functional variables. Heart 2002; 87(3):235–41. http://www.ncbi.nlm.nih.gov/pubmed/11847161.

65. Rutledge T, Reis VA, Linke SE, et al. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 2006; 48(8):1527–37. http://www.ncbi.nlm.nih.gov/pubmed/17045884.

66. Gathright EC, Goldstein CM, Josephson RA, et al. Depression increases the risk of mortality in patients with heart failure: A meta-analysis. J Psychosom Res 2017; 94:82–9. DOI: 10.1016/j.jpsychores.2017.01.010. http://www.ncbi.nlm.nih.gov/pubmed/28183407.

67. Bandelow B, Wiltink J, Alpers GW, et al. S3-Leitlinie Behandlung von Angststörungen. 2014 [cited: 2019-10-02]. https://www.awmf.org/uploads/tx_szleitlinien/051-028l_S3_Angstst%C3%B6rungen_2014-05-abgelaufen.pdf.

68. Deutschsprachige Gesellschaft für Psychotraumatologie (DeGPT), Deutsche Gesellschaft für Psychotherapeutische Medizin und ärztliche Psychotherapie (DGPM), Deutsches Kollegium für Psychosomatische Medizin (DKPM), et al. S3-Leitlinie. Posttraumatische Belastungsstörung. ICD 10: F 43.1. 2011 [cited: 2019-03-07]. https://www.awmf.org/uploads/tx_szleitlinien/051-010l_S3_Posttraumatische_Belastungsstoerung_2012-abgelaufen.pdf.

69. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN), Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), et al. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression - Langfassung, 2. Auflage. Version 5. 2015 [cited: 2018-06-06]. DOI: 10.6101/AZQ/000364. http://doi.org/10.6101/AZQ/000364.

70. Herrmann-Lingen C, Buss U, Snaith RP. Hospital Anxiety and Depression Scale - Deutsche Version (HADS-D). Manual. Berlin: Huber; 1993.

71. Herrmann-Lingen C., Buss U., Snaith R.P. Hospital Anxiety and Depression Scale - deutsche Version (HADS-D). 3rd ed. Bern: Huber; 2011.

72. Löwe B, Spitzer RL, Zipfel S, et al. PHQ-D - Gesundheitsfragebogen für Patienten. Karlsruhe: Pfizer; 2001.

73. Löwe B, Spitzer RL, Gräfe K, et al. Comparative validity of three screening questionnaires for DSM-IV depressive disorders and physicians‘ diagnoses. J Affect. Disord 2004; 78(2):131–40. http://www.ncbi.nlm.nih.gov/pubmed/14706723.

74. Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety disorder: The GAD-7. Arch. Intern. Med 2006; 166(10):1092–7. DOI: 10.1001/archinte.166.10.1092. http://www.ncbi.nlm.nih.gov/pubmed/16717171.

75. Löwe B, Decker O, Müller S, et al. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med Care 2008; 46(3):266–74. DOI: 10.1097/MLR.0b013e318160d093. http://www.ncbi.nlm.nih.gov/pubmed/18388841.

76. Kroenke K, Spitzer RL, Williams JB, et al. Anxiety disorders in primary care: Prevalence, impairment, comorbidity, and detection. Ann Intern Med 2007; 146(5):317–25. http://www.ncbi.nlm.nih.gov/pubmed/17339617.

77. Maercker A, Schützwohl M. Erfassung von psychischen Belastungsfolgen: Die Impact of Event Skala-revidierte Version (IES-R)). Diagnostica 1998; 44(3):130–41.

78. Toussaint A, Riedl B, Kehrer S, et al. Validity of the Somatic Symptom Disorder-B Criteria Scale (SSD-12) in primary care. Fam Pract 2018; 35(3):342–7. DOI: 10.1093/fampra/cmx116. http://www.ncbi.nlm.nih.gov/pubmed/29145575.

79. Toussaint A, Löwe B, Brähler E, et al. The Somatic Symptom Disorder - B Criteria Scale (SSD-12): Factorial structure, validity and population-based norms. J Psychosom Res 2017; 97:9–17. DOI: 10.1016/j.jpsychores.2017.03.017. http://www.ncbi.nlm.nih.gov/pubmed/28606504.

80. Herzog A, Voigt K, Meyer B, et al. Der Fragebogen zum Erleben von Körperbeschwerden (SSEQ): Ein neues Selbstbeurteilungsinstrument zur Erfassung der psychischen Merkmale somatoformer Störungen. Psychother Psychosom Med Psychol 2014; 64(3-4):115–21. DOI: 10.1055/s-0032-1333303. http://www.ncbi.nlm.nih.gov/pubmed/23864304.

81. Unverzagt S, Meyer G, Mittmann S, et al. Improving Treatment Adherence in Heart Failure. Dtsch Arztebl Int 2016; 113(25):423–30. DOI: 10.3238/arztebl.2016.0423. http://www.ncbi.nlm.nih.gov/pubmed/27397013.

82. Schulz M, Krueger K, Schuessel K, et al. Medication adherence and persistence according to different antihypertensive drug classes: A retrospective cohort study of 255,500 patients. Int J Cardiol 2016; 220:668–76. DOI: 10.1016/j.ijcard.2016.06.263. http://www.ncbi.nlm.nih.gov/pubmed/27393848.

83. McLellan J, Heneghan CJ, Perera R, et al. B-type natriuretic peptide-guided treatment for heart failure. Cochrane Database Syst Rev 2016; 12(12):CD008966. DOI: 10.1002/14651858.CD008966.pub2. http://www.ncbi.nlm.nih.gov/pubmed/28102899.

84. Bundesministerium der Justiz und für Verbraucherschutz (BMJV). § 630e Aufklärungspflichten. In: Bundesministerium der Justiz und für Verbraucherschutz (BMJV), editor. Bürgerliches Gesetzbuch (BGB); 2017.

85. Stacey D, Légaré F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2017; 4(4):CD001431. DOI: 10.1002/14651858.CD001431.pub5. http://www.ncbi.nlm.nih.gov/pubmed/28402085.

86. Kane PM, Murtagh FE, Ryan K, et al. The gap between policy and practice: A systematic review of patient-centred care interventions in chronic heart failure. Heart Fail Rev 2015; 20(6):673–87. DOI: 10.1007/s10741-015-9508-5. http://www.ncbi.nlm.nih.gov/pubmed/26435042.

87. Scherer M, Wagner H.O., Lühmann D, et al. Multimorbidität. S3-Leitlinie. AWMF-Register-Nr. 053-047. 2017 (DEGAM-Leitlinie; 20) [cited: 2018-06-06]. http://www.degam.de/files/Inhalte/Leitlinien-Inhalte/Dokumente/DEGAM-S3-Leitlinien/
053-047_Multimorbiditaet/053-047l_%20Multimorbiditaet_redakt_24-1-18.pdf
.

88. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch. Intern. Med 2002; 162(15):1682–8. http://www.ncbi.nlm.nih.gov/pubmed/12153370.

89. Cherubini A, Oristrell J, Pla X, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch. Intern. Med 2011; 171(6):550–6. DOI: 10.1001/archinternmed.2011.31. http://www.ncbi.nlm.nih.gov/pubmed/21444844.

90. Leigh-Hunt N, Bagguley D, Bash K, et al. An overview of systematic reviews on the public health consequences of social isolation and loneliness. Public Health 2017; 152:157–71. DOI: 10.1016/j.puhe.2017.07.035. http://www.ncbi.nlm.nih.gov/pubmed/28915435.

91. Stringhini S, Berkman L, Dugravot A, et al. Socioeconomic status, structural and functional measures of social support, and mortality: The British Whitehall II Cohort Study, 1985-2009. Am J Epidemiol 2012; 175(12):1275–83. DOI: 10.1093/aje/kwr461. http://www.ncbi.nlm.nih.gov/pubmed/22534202.

92. Mattila M, Boehm L, Burke S, et al. Nonprescription medication use in patients with heart failure: Assessment methods, utilization patterns, and discrepancies with medical records. J Card Fail 2013; 19(12):811–5. DOI: 10.1016/j.cardfail.2013.10.009. http://www.ncbi.nlm.nih.gov/pubmed/24184371.

93. Stewart AL, Lynch KJ. Identifying discrepancies in electronic medical records through pharmacist medication reconciliation. J Am Pharm Assoc (Wash. ) 2012; 52(1):59–66. DOI: 10.1331/JAPhA.2012.10123. http://www.ncbi.nlm.nih.gov/pubmed/22257617.

94. Laufs U, Böhm M, Kroemer HK, et al. Strategien zur Verbesserung der Einnahmetreue von Medikamenten. Dtsch Med Wochenschr 2011; 136(31-32):1616–21. http://www.ncbi.nlm.nih.gov/pubmed/21809255.

95. Michalsen A, König G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart 1998; 80(5):437–41. http://www.ncbi.nlm.nih.gov/pubmed/9930040.

96. Lee D, Mansi I, Bhushan S, Parish R. Non-Adherence in At-Risk Heart Failure Patients: Characteristics and Outcomes. Journal of Nature and Science (JNSCI) 2015; 1(5):e95. http://www.jnsci.org/files/article/e95.pdf.

97. Rice H, Say R, Betihavas V. The effect of nurse-led education on hospitalisation, readmission, quality of life and cost in adults with heart failure. A systematic review. Patient Educ Couns 2017; 101(3):363-374. DOI: 10.1016/j.pec.2017.10.002. http://www.ncbi.nlm.nih.gov/pubmed/29102442.

98. Srisuk N, Cameron J, Ski CF, et al. Heart failure family-based education: A systematic review. Patient Educ Couns 2016; 99(3):326–38. DOI: 10.1016/j.pec.2015.10.009. http://www.ncbi.nlm.nih.gov/pubmed/26519992.

99. van Spall HG, Rahman T, Mytton O, et al. Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: A systematic review and network meta-analysis. Eur J Heart Fail 2017; 19(11):1427–43. DOI: 10.1002/ejhf.765. http://www.ncbi.nlm.nih.gov/pubmed/28233442.

100. Oyanguren J, Latorre García PM, Torcal Laguna J, et al. Effectiveness and Factors Determining the Success of Management Programs for Patients With Heart Failure: A Systematic Review and Meta-analysis. Rev Esp Cardiol (Engl Ed) 2016; 69(10):900–14. DOI: 10.1016/j.rec.2016.05.012. http://www.ncbi.nlm.nih.gov/pubmed/27692124.

101. Casimir YE, Williams MM, Liang MY, et al. The effectiveness of patient-centered self-care education for adults with heart failure on knowledge, self-care behaviors, quality of life, and readmissions: A systematic review. JBI Database System Rev Implement Rep 2014(2):188–262. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0068692.

102. Glatz J, Muschalla B, Karger G. Patientenschulung bei Herzinsuffizienz verbessert krankheitsbezogenes Wissen und Verhalten während kardiologischer Rehabilitation. Rehabilitation (Stuttg) 2014; 53(3):155–60. DOI: 10.1055/s-0033-1351312. http://www.ncbi.nlm.nih.gov/pubmed/24390871.

103. Meng K, Musekamp G, Schuler M, et al. The impact of a self-management patient education program for patients with chronic heart failure undergoing inpatient cardiac rehabilitation. Patient Educ Couns. 2016; 99(7):1190–7. DOI: 10.1016/j.pec.2016.02.010. http://www.ncbi.nlm.nih.gov/pubmed/26898600.

104. Deutsche Rentenversicherung Bund (DRV-Bund). Curriculum Herzinsuffizienz. Standardisierte Patientenschulung. 2015 [cited: 2018-05-24]. https://www.deutsche-rentenversicherung.de/SharedDocs/Downloads/DE/Experten/
infos_reha_einrichtungen/gesundheitstraining/kardiologie_herzinsuffizienz.html
.

105. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz - Langfassung, 1. Auflage. Version 7. 2009 [cited: 2017-09-20]. DOI: 10.6101/AZQ/000166. http://doi.org/10.6101/AZQ/000166.

106. Hegde SM, Claggett B, Shah AM, et al. Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist). Circulation 2017; 136(11):982–92. DOI: 10.1161/CIRCULATIONAHA.117.028002. http://www.ncbi.nlm.nih.gov/pubmed/28637881.

107. Doukky R, Mangla A, Ibrahim Z, et al. Impact of Physical Inactivity on Mortality in Patients With Heart Failure. Am J Cardiol 2016; 117(7):1135–43. DOI: 10.1016/j.amjcard.2015.12.060. http://www.ncbi.nlm.nih.gov/pubmed/26853954.

108. Kraigher-Krainer E, Lyass A, Massaro JM, et al. Association of physical activity and heart failure with preserved vs. reduced ejection fraction in the elderly: The Framingham Heart Study. Eur J Heart Fail 2013; 15(7):742–6. DOI: 10.1093/eurjhf/hft025. http://www.ncbi.nlm.nih.gov/pubmed/23435761.

109. Taylor RS, Sagar VA, Davies EJ, et al. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev 2014(4):CD003331. DOI: 10.1002/14651858.CD003331.pub4. http://www.ncbi.nlm.nih.gov/pubmed/24771460.

110. Psotka MA, Maltzahn R von, Anatchkova M, et al. Patient-Reported Outcomes in Chronic Heart Failure: Applicability for Regulatory Approval. JACC. Heart failure 2016; 4(10):791–804. DOI: 10.1016/j.jchf.2016.04.010. http://www.ncbi.nlm.nih.gov/pubmed/27395351.

111. Ostman C, Jewiss D, Smart NA. The Effect of Exercise Training Intensity on Quality of Life in Heart Failure Patients: A Systematic Review and Meta-Analysis. Cardiology 2017; 136(2):79–89. DOI: 10.1159/000448088. http://www.ncbi.nlm.nih.gov/pubmed/27577715.

112. Chan E, Giallauria F, Vigorito C, et al. Exercise training in heart failure patients with preserved ejection fraction: A systematic review and meta-analysis. Monaldi Arch Chest Dis 2016; 86(1-2):759. DOI: 10.4081/monaldi.2016.759. http://www.ncbi.nlm.nih.gov/pubmed/27748473.

113. Jewiss D, Ostman C, Smart NA. The effect of resistance training on clinical outcomes in heart failure: A systematic review and meta-analysis. Int J Cardiol 2016; 221:674–81. DOI: 10.1016/j.ijcard.2016.07.046. http://www.ncbi.nlm.nih.gov/pubmed/27423089.

114. Dieberg G, Ismail H, Giallauria F, et al. Clinical outcomes and cardiovascular responses to exercise training in heart failure patients with preserved ejection fraction: A systematic review and meta-analysis. J Appl Physiol (1985) 2015; 119(6):726–33. DOI: 10.1152/japplphysiol.00904.2014. http://www.ncbi.nlm.nih.gov/pubmed/25749444.

115. Pandey A, Parashar A, Kumbhani D, et al. Exercise training in patients with heart failure and preserved ejection fraction: Meta-analysis of randomized control trials. Circ Heart Fail 2015; 8(1):33–40. DOI: 10.1161/CIRCHEARTFAILURE.114.001615. http://www.ncbi.nlm.nih.gov/pubmed/25399909.

116. Zwisler A-D, Norton RJ, Dean SG, et al. Home-based cardiac rehabilitation for people with heart failure: A systematic review and meta-analysis. Int J Cardiol 2016; 221:963–9. DOI: 10.1016/j.ijcard.2016.06.207. http://www.ncbi.nlm.nih.gov/pubmed/27441476.

117. Cornelis J, Beckers P, Taeymans J, et al. Comparing exercise training modalities in heart failure: A systematic review and meta-analysis. Int J Cardiol 2016; 221:867–76. DOI: 10.1016/j.ijcard.2016.07.105. http://www.ncbi.nlm.nih.gov/pubmed/27434363.

118. Ellingsen O, Halle M, Conraads V, et al. High-Intensity Interval Training in Patients With Heart Failure With Reduced Ejection Fraction. Circulation 2017; 135(9):839–49. DOI: 10.1161/CIRCULATIONAHA.116.022924. http://www.ncbi.nlm.nih.gov/pubmed/28082387.

119. Palau P, Nunez E, Dominguez E, et al. Physical therapy in heart failure with preserved ejection fraction: A systematic review. Eur J Prev Cardiol 2016; 23(1):4–13. DOI: 10.1177/2047487314562740. http://www.ncbi.nlm.nih.gov/pubmed/25488549.

120. Fletcher GF, Ades PA, Kligfield P, et al. Exercise standards for testing and training: A scientific statement from the American Heart Association. Circulation 2013; 128(8):873–934. DOI: 10.1161/CIR.0b013e31829b5b44. http://www.ncbi.nlm.nih.gov/pubmed/23877260.

121. Mezzani A, Hamm LF, Jones AM, et al. Aerobic exercise intensity assessment and prescription in cardiac rehabilitation: A joint position statement of the European Association for Cardiovascular Prevention and Rehabilitation, the American Association of Cardiovascular and Pulmonary Rehabilitation and the Canadian Association of Cardiac Rehabilitation. Eur J Prev Cardiol 2013; 20(3):442–67. DOI: 10.1177/2047487312460484. http://www.ncbi.nlm.nih.gov/pubmed/23104970.

122. Anderson L, Sharp GA, Norton RJ, et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst Rev 2017; 6:CD007130. DOI: 10.1002/14651858.CD007130.pub4. http://www.ncbi.nlm.nih.gov/pubmed/28665511.

123. O‘Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009; 301(14):1439–50. http://www.ncbi.nlm.nih.gov/pubmed/19351941.

124. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29):2315–81. DOI: 10.1093/eurheartj/ehw106. http://www.ncbi.nlm.nih.gov/pubmed/27222591.

125. Deutsche Gesellschaft für Prävention und Rehabilitationvon Herz-Kreislauferkrankungen (DGPR), Bjarnason-Weherns B. Leitlinie körperliche Aktivität zur Sekundärprävention und Therapie kardiovaskulärer Erkrankungen. Clin Res Cardiol. Suppl 2009; 4(4 Suppl):1–44. DOI: 10.1007/s11789-009-0078-8.

126. Li Y, Fu B, Qian X. Liberal versus restricted fluid administration in heart failure patients. A systematic review and meta-analysis of randomized trials. Int Heart J 2015; 56(2):192–5. DOI: 10.1536/ihj.14-288. http://www.ncbi.nlm.nih.gov/pubmed/25740394.

127. Castro-Gutierrez V, Rada G. Should sodium intake be restricted in chronic heart failure? Medwave. 2016; 16(5 Suppl):e6696. http://www.ncbi.nlm.nih.gov/pubmed/27922584.

128. Deutsche Gesellschaft für Ernährung, Österreichische Gesellschaft für Ernährung, Schweizerische Gesellschaft für Ernährungsforschung. D-A-CH-Referenzwerte für die Nährstoffzufuhr. 2. Aufl. ed. Neustadt/Weinstraße: Neuer Umschau Buchverl.; 2015.

129. Sharma A, Lavie CJ, Borer JS, et al. Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. Am J Cardiol 2015; 115(10):1428–34. DOI: 10.1016/j.amjcard.2015.02.024. http://www.ncbi.nlm.nih.gov/pubmed/25772740.

130. Padwal R, McAlister FA, McMurray JJ, et al. The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: A meta-analysis of individual patient data. Int J Obes (Lond) 2014; 38(8):1110–4. DOI: 10.1038/ijo.2013.203. http://www.ncbi.nlm.nih.gov/pubmed/24173404.

131. Oga EA, Eseyin OR. The Obesity Paradox and Heart Failure: A Systematic Review of a Decade of Evidence. J Obes 2016; 2016:9040248. DOI: 10.1155/2016/9040248. http://www.ncbi.nlm.nih.gov/pubmed/26904277.

132. Piepoli MF, Corrà U, Veglia F, et al. Exercise tolerance can explain the obesity paradox in patients with systolic heart failure: Data from the MECKI Score Research Group. Eur J Heart Fail 2016; 18(5):545–53. DOI: 10.1002/ejhf.534. http://www.ncbi.nlm.nih.gov/pubmed/27135769.

133. Barry VW, Baruth M, Beets MW, et al. Fitness vs. fatness on all-cause mortality: A meta-analysis. Prog Cardiovasc Dis 2014; 56(4):382–90. DOI: 10.1016/j.pcad.2013.09.002. http://www.ncbi.nlm.nih.gov/pubmed/24438729.

134. Lavie CJ, Cahalin LP, Chase P, et al. Impact of cardiorespiratory fitness on the obesity paradox in patients with heart failure. Mayo Clin Proc 2013; 88(3):251–8. DOI: 10.1016/j.mayocp.2012.11.020. http://www.ncbi.nlm.nih.gov/pubmed/23489451.

135. Agrawal RP, Choudhary R, Sharma P, et al. Glyceryl trinitrate spray in the management of painful diabetic neuropathy: A randomized double blind placebo controlled cross-over study. Diabetes Res Clin Pract 2007; 77(2):161–7. http://www.ncbi.nlm.nih.gov/pubmed/17316865.

136. Horwich TB, Broderick S, Chen L, et al. Relation among body mass index, exercise training, and outcomes in chronic systolic heart failure. Am J Cardiol 2011; 108(12):1754–9. DOI: 10.1016/j.amjcard.2011.07.051. http://www.ncbi.nlm.nih.gov/pubmed/21907317.

137. Edelmann F, Gelbrich G, Düngen H-D, et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: Results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol 2011; 58(17):1780–91. DOI: 10.1016/j.jacc.2011.06.054. http://www.ncbi.nlm.nih.gov/pubmed/21996391.

138. Hauner H, Buchholz G, Hamann A, et al. Prävention und Therapie der Adipositas. Version 2.0. 2014 [cited: 2018-04-05]. http://www.awmf.org/uploads/tx_szleitlinien/050-001l_S3_Adipositas_Pr%C3%A4vention_Therapie_2014-11.pdf.

139. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV), Deutsche Adipositas-Gesellschaft (DAG). S3-Leitlinie: Chirurgie der Adipositas und metabolischer Erkrankungen. 2018 [cited: 2019-03-06]. https://www.awmf.org/uploads/tx_szleitlinien/088-001l_S3_Chirurgie-Adipositas-metabolische-Erkrankugen_2018-02.pdf.

140. Suskin N, Sheth T, Negassa A, et al. Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am Coll Cardiol 2001; 37(6):1677–82. http://www.ncbi.nlm.nih.gov/pubmed/11345383.

141. Shah AM, Pfeffer MA, Hartley LH, et al. Risk of all-cause mortality, recurrent myocardial infarction, and heart failure hospitalization associated with smoking status following myocardial infarction with left ventricular dysfunction. Am. J. Cardiol. 2010; 106(7):911–6. DOI: 10.1016/j.amjcard.2010.05.021. http://www.ncbi.nlm.nih.gov/pubmed/20854949.

142. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN), Deutsche Gesellschaft für Suchtforschung und Suchttherapie (DG-Sucht), et al. S3-Leitlinie „Screening, Diagnostik und Behandlung des schädlichen und abhängigen Tabakkonsums“. AWMF-Register Nr. 076-006. (Stand: 09.02.2015). 2014 [cited: 2018-09-13]. http://www.awmf.org/uploads/tx_szleitlinien/076-006l_S3_Tabak_2015-02.pdf.

143. Guillo P, Mansourati J, Maheu B, et al. Long-term prognosis in patients with alcoholic cardiomyopathy and severe heart failure after total abstinence. Am. J. Cardiol. 1997; 79(9):1276–8. http://www.ncbi.nlm.nih.gov/pubmed/9164905.

144. Jacob AJ, McLaren KM, Boon NA. Effects of abstinence on alcoholic heart muscle disease. Am. J. Cardiol. 1991; 68(8):805–7. http://www.ncbi.nlm.nih.gov/pubmed/1892094.

145. Nicolas JM, Fernandez-Sola J, Estruch R, et al. The effect of controlled drinking in alcoholic cardiomyopathy. Ann Intern Med 2002; 136(3):192–200. http://www.ncbi.nlm.nih.gov/pubmed/11827495.

146. Cosmi F, Di Giulio P, Masson S, et al. Regular wine consumption in chronic heart failure: Impact on outcomes, quality of life, and circulating biomarkers. Circ Heart Fail 2015; 8(3):428–37. DOI: 10.1161/CIRCHEARTFAILURE.114.002091. http://www.ncbi.nlm.nih.gov/pubmed/25925415.

147. Petrone AB, Gaziano JM, Djoussé L. Alcohol consumption and risk of death in male physicians with heart failure. Am J Cardiol 2014; 114(7):1065–8. DOI: 10.1016/j.amjcard.2014.07.021. http://www.ncbi.nlm.nih.gov/pubmed/25129877.

148. Barlow J, Wright C, Sheasby J, et al. Self-management approaches for people with chronic conditions: A review. Patient Educ Couns. 2002; 48(2):177–87. http://www.ncbi.nlm.nih.gov/pubmed/12401421.

149. Wenger NS, Young RT. Quality indicators for continuity and coordination of care in vulnerable elders. J Am Geriatr Soc 2007; 55 Suppl 2:S285-S292. DOI: 10.1111/j.1532-5415.2007.01334.x. http://www.ncbi.nlm.nih.gov/pubmed/17910549.

150. Kuske S, Lessing C, Lux R, et al. Patientensicherheitsindikatoren zur Arzneimitteltherapiesicherheit (AMTS-PSI): Internationaler Status, Übertragbarkeit und Validierung. Gesundheitswesen 2012; 74(2):79–86. DOI: 10.1055/s-0030-1269838. http://www.ncbi.nlm.nih.gov/pubmed/21229474.

151. Lapi F, Azoulay L, Yin H, et al. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: Nested case-control study. BMJ 2013; 346:e8525. http://www.ncbi.nlm.nih.gov/pubmed/23299844.

152. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J Med 2004; 351(6):543–51. http://www.ncbi.nlm.nih.gov/pubmed/15295047.

153. Cleland JG, Erhardt L, Murray G, et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J 1997; 18(1):41–51. http://www.ncbi.nlm.nih.gov/pubmed/9049514.

154. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333(25):1670–6. http://www.ncbi.nlm.nih.gov/pubmed/7477219.

155. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327(10):669–77. http://www.ncbi.nlm.nih.gov/pubmed/1386652.

156. Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: A follow-up study. Lancet 2003; 361(9372):1843–8. http://www.ncbi.nlm.nih.gov/pubmed/12788569.

157. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273(18):1450–6. http://www.ncbi.nlm.nih.gov/pubmed/7654275.

158. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: A meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41(9):1529–38. http://www.ncbi.nlm.nih.gov/pubmed/12742294.

159. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355(9215):1575–81. http://www.ncbi.nlm.nih.gov/pubmed/10821360.

160. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316(23):1429–35. http://www.ncbi.nlm.nih.gov/pubmed/2883575.

161. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325(5):293–302. http://www.ncbi.nlm.nih.gov/pubmed/2057034.

162. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327(10):685–91. http://www.ncbi.nlm.nih.gov/pubmed/1463530.

163. Hutcheon SD, Gillespie ND, Crombie IK, et al. Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: A randomised double blind placebo controlled trial. Heart 2002; 88(4):373–7. http://www.ncbi.nlm.nih.gov/pubmed/12231595.

164. Gambassi G, Lapane KL, Sgadari A, et al. Effects of angiotensin-converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology. Arch. Intern. Med 2000; 160(1):53–60. http://www.ncbi.nlm.nih.gov/pubmed/10632305.

165. Zuccala G, Onder G, Marzetti E, et al. Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure. Eur Heart J 2005; 26(3):226–33. http://www.ncbi.nlm.nih.gov/pubmed/15618043.

166. The NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J 1998; 19(3):481–9. http://www.ncbi.nlm.nih.gov/pubmed/9568453.

167. Nanas JN, Alexopoulos G, Anastasiou-Nana MI, et al. Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: A multicenter study. High Enalapril Dose Study Group. J Am Coll Cardiol 2000; 36(7):2090–5. http://www.ncbi.nlm.nih.gov/pubmed/11127445.

168. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100(23):2312–8. http://www.ncbi.nlm.nih.gov/pubmed/10587334.

169. Mackay FJ, Pearce GL, Mann RD. Cough and angiotensin II receptor antagonists: Cause or confounding? Br J Clin Pharmacol 1999; 47(1):111–4. http://www.ncbi.nlm.nih.gov/pubmed/10073748.

170. Kubota K, Kubota N, Pearce GL, et al. ACE-inhibitor-induced cough, an adverse drug reaction unrecognised for several years: Studies in prescription-event monitoring. Eur J Clin Pharmacol 1996; 49(6):431–7. http://www.ncbi.nlm.nih.gov/pubmed/8706766.

171. Strocchi E, Malini PL, Valtancoli G, et al. Cough during treatment with angiotensin-converting enzyme inhibitors. Analysis of predisposing factors. Drug Invest 1992; 4:69–72.

172. Hicks BM, Filion KB, Yin H, et al. Angiotensin converting enzyme inhibitors and risk of lung cancer: Population based cohort study. BMJ (Clinical research ed.) 2018; 363:k4209. DOI: 10.1136/bmj.k4209. http://www.ncbi.nlm.nih.gov/pubmed/30355745.

173. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100(10):1056–64. http://www.ncbi.nlm.nih.gov/pubmed/10477530.

174. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355(9215):1582–7. http://www.ncbi.nlm.nih.gov/pubmed/10821361.

175. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360(9335):752–60. http://www.ncbi.nlm.nih.gov/pubmed/12241832.

176. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J Med 2003; 349(20):1893–906. http://www.ncbi.nlm.nih.gov/pubmed/14610160.

177. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet 2003; 362(9386):772–6. http://www.ncbi.nlm.nih.gov/pubmed/13678870.

178. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345(23):1667–75. http://www.ncbi.nlm.nih.gov/pubmed/11759645.

179. Lee VC, Rhew DC, Dylan M, et al. Meta-analysis: Angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004; 141(9):693–704. http://www.ncbi.nlm.nih.gov/pubmed/15520426.

180. Jong P, Demers C, McKelvie RS, et al. Angiotensin receptor blockers in heart failure: Meta-analysis of randomized controlled trials. J Am Coll Cardiol 2002; 39(3):463–70. http://www.ncbi.nlm.nih.gov/pubmed/11823085.

181. Heran BS, Musini VM, Bassett K, et al. Angiotensin receptor blockers for heart failure. Cochrane Database Syst Rev 2012; 4:CD003040. DOI: 10.1002/14651858.CD003040.pub2. http://www.ncbi.nlm.nih.gov/pubmed/22513909.

182. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 2003; 362(9386):767–71. http://www.ncbi.nlm.nih.gov/pubmed/13678869.

183. Dimopoulos K, Salukhe TV, Coats AJ, et al. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker). Int J Cardiol 2004; 93(2-3):105–11. http://www.ncbi.nlm.nih.gov/pubmed/14975535.

184. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999; 353(9146):9–13. http://www.ncbi.nlm.nih.gov/pubmed/10023943.

185. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000; 283(10):1295–302. http://www.ncbi.nlm.nih.gov/pubmed/10714728.

186. Krum H, Roecker EB, Mohacsi P, et al. Effects of initiating carvedilol in patients with severe chronic heart failure: Results from the COPERNICUS Study. JAMA 2003; 289(6):712–8. http://www.ncbi.nlm.nih.gov/pubmed/12585949.

187. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344(22):1651–8. http://www.ncbi.nlm.nih.gov/pubmed/11386263.

188. Erdmann E, Lechat P, Verkenne P, et al. Results from post-hoc analyses of the CIBIS II trial: Effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001; 3(4):469–79. http://www.ncbi.nlm.nih.gov/pubmed/11511434.

189. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26(3):215–25. http://www.ncbi.nlm.nih.gov/pubmed/15642700.

190. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353(9169):2001–7. http://www.ncbi.nlm.nih.gov/pubmed/10376614.

191. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344(22):1659–67. http://www.ncbi.nlm.nih.gov/pubmed/11386264.

192. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 2003; 362(9377):7–13. http://www.ncbi.nlm.nih.gov/pubmed/12853193.

193. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet 2001; 357(9266):1385–90. http://www.ncbi.nlm.nih.gov/pubmed/11356434.

194. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334(21):1349–55. http://www.ncbi.nlm.nih.gov/pubmed/8614419.

195. Kaiser T, Jennen E, Sawicki PT. Entscheidungsgrundlage zur evidenzbasierten Diagnostik und Therapie bei Disease Management Programmen für Herzinsuffizienz bei systolischer linksventrikulärer Dysfunktion. 2., überarbeitete Version. Köln: DIeM; 2003.

196. Kotecha D, Holmes J, Krum H, et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: An individual-patient data meta-analysis. Lancet 2014; 384(9961):2235–43. http://www.ncbi.nlm.nih.gov/pubmed/25193873.

197. Willenheimer R, van Veldhuisen DJ, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: Results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005; 112(16):2426–35. http://www.ncbi.nlm.nih.gov/pubmed/16143696.

198. Jondeau G, Neuder Y, Eicher JC, et al. B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J 2009; 30(18):2186–92. DOI: 10.1093/eurheartj/ehp323. http://www.ncbi.nlm.nih.gov/pubmed/19717851.

199. Passos LC, Oliveira MG, Duraes AR, et al. Initiation or maintenance of beta-blocker therapy in patients hospitalized for acute heart failure. Int J Clin Pharm 2016; 38(4):802–7. DOI: 10.1007/s11096-016-0265-x. http://www.ncbi.nlm.nih.gov/pubmed/27138843.

200. Miro O, Muller C, Martin-Sanchez FJ, et al. BETAWIN-AHF study: Effect of beta-blocker withdrawal during acute decompensation in patients with chronic heart failure. Clin Res Cardiol 2016; 105(12):1021–9. DOI: 10.1007/s00392-016-1014-9. http://www.ncbi.nlm.nih.gov/pubmed/27379611.

201. Prins KW, Neill JM, Tyler JO, et al. Effects of Beta-Blocker Withdrawal in Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis. JACC Heart Fail 2015; 3(8):647–53. DOI: 10.1016/j.jchf.2015.03.008. http://www.ncbi.nlm.nih.gov/pubmed/26251094.

202. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341(10):709–17. http://www.ncbi.nlm.nih.gov/pubmed/10471456.

203. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J Med 2003; 348(14):1309–21. http://www.ncbi.nlm.nih.gov/pubmed/12668699.

204. Vizzardi E, D‘Aloia A, Giubbini R, et al. Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure. Am. J. Cardiol. 2010; 106(9):1292–6. DOI: 10.1016/j.amjcard.2010.06.052. http://www.ncbi.nlm.nih.gov/pubmed/21029826.

205. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364(1):11–21. DOI: 10.1056/NEJMoa1009492. http://www.ncbi.nlm.nih.gov/pubmed/21073363.

206. Hu LJ, Chen YQ, Deng SB, et al. Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: A systematic review and meta-analysis. Br J Clin Pharmacol 2013; 75(5):1202–12. DOI: 10.1111/bcp.12012. http://www.ncbi.nlm.nih.gov/pubmed/23088367.

207. Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ). Hydrochlorothiazid - Risiko von nichtmelanozytärem Hautkrebs [Basalzellkarzinom (Basaliom); Plattenepithelkarzinom der Haut (Spinaliom)]. Rote-Hand-Brief vom 17.Oktober 2018. 2018 [cited: 2019-01-18]. https://www.akdae.de/Arzneimittelsicherheit/RHB/20181017.pdf.

208. Pottegård A, Hallas J, Olesen M, et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med 2017; 282(4):322–31. DOI: 10.1111/joim.12629. http://www.ncbi.nlm.nih.gov/pubmed/28480532.

209. Pedersen SA, Gaist D, Schmidt SA, et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. Journal of the American Academy of Dermatology 2018; 78(4):673-681.e9. DOI: 10.1016/j.jaad.2017.11.042. http://www.ncbi.nlm.nih.gov/pubmed/29217346.

210. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371(11):993–1004. DOI: 10.1056/NEJMoa1409077. http://www.ncbi.nlm.nih.gov/pubmed/25176015.

211. Jhund PS, Fu M, Bayram E, et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: Insights from PARADIGM-HF. Eur Heart J 2015; 36(38):2576–84. DOI: 10.1093/eurheartj/ehv330. http://www.ncbi.nlm.nih.gov/pubmed/26231885.

212. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Sacubitril/Valsartan - Addendum zum Auftrag A15-60. Addendum. Auftrag A16-29. Version 1.0. 2016 (IQWiG-Berichte; 394) [cited: 2019-10-01]. http://www.g-ba.de/downloads/92-975-1411/Addendum%20zur%20Nutzenbewertung%20des%20IQWiG_Sacubitril_Valsartan.pdf.

213. Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med 2019; 380(6):539–48. DOI: 10.1056/NEJMoa1812851. http://www.ncbi.nlm.nih.gov/pubmed/30415601.

214. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Sacubitril/Valsartan - Nutzenbewertung gemäβ § 35a SGB V. Dossierbewertung. Auftrag: A15-60. Version: 1.0. 2016 (IQWiG-Berichte; 379) [cited: 2019-10-01]. http://www.iqwig.de/download/A15-60_Sacubitril-Valsartan_Nutzenbewertung-35a-SGB-V.pdf.

215. Gemeinsamer Bundesausschuss (G-BA). Dossier zur Nutzenbewertung gemäβ § 35a SGB V. Sacubitril/Valsartan (Entresto®) Modul 4 A. Erwachsene Patienten mit symptomatischer, chronischer Herzinsuffizienz mit reduzierter Ejektionsfraktion. 2015 [cited: 2019-10-01]. http://www.g-ba.de/downloads/92-975-1312/2015-12-21_Modul4A_Sacubitril-Valsartan.pdf.

216. Novartis Pharma, Rote Liste/Fachinfo-Service. Entresto® Filmtabletten. Fachinformation. 2016 [cited: 2017-02-22]. http://www.fachinfo.de.

217. Feldman AM, Haller JA, DeKosky ST. Valsartan/Sacubitril for Heart Failure: Reconciling Disparities Between Preclinical and Clinical Investigations. JAMA 2016; 315(1):25–6. DOI: 10.1001/jama.2015.17632. http://www.ncbi.nlm.nih.gov/pubmed/26641736.

218. Food and Drug Administration (FDA). Entresto Label and Approval History. 2015 [cited: 2019-10-01]. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/207620Orig1s000ltr.pdf.

219. Food and Drug Administration (FDA). Entresto. Clinical Pharmacology Review. 2014 [cited: 2018-09-06]. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207620Orig1s000ClinPharmR.pdf.

220. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet 2010; 376(9744):875–85. DOI: 10.1016/S0140-6736(10)61198-1. http://www.ncbi.nlm.nih.gov/pubmed/20801500.

221. Swedberg K, Komajda M, Bohm M, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: Is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol 2012; 59(22):1938–45. DOI: 10.1016/j.jacc.2012.01.020. http://www.ncbi.nlm.nih.gov/pubmed/22617188.

222. Bohm M, Borer J, Ford I, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: Analysis from the SHIFT study. Clin Res Cardiol 2013; 102(1):11–22. DOI: 10.1007/s00392-012-0467-8. http://www.ncbi.nlm.nih.gov/pubmed/22575988.

223. Fox K, Komajda M, Ford I, et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: A pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Eur Heart J 2013; 34(29):2263–70. DOI: 10.1093/eurheartj/eht101. http://www.ncbi.nlm.nih.gov/pubmed/23536611.

224. Servier Deutschland GmbH, Rote Liste/Fachinfo-Service. Procoralan®. Fachinformation. 2015 [cited: 2016-07-17]. http://www.fachinfo.de.

225. Kosiuk J, Lindemann F, Hindricks G, et al. Need for further studies on ivabradine in patients with persistent atrial fibrillation. Int J Cardiol 2016; 223:915–6. DOI: 10.1016/j.ijcard.2016.08.329. http://www.ncbi.nlm.nih.gov/pubmed/27589039.

226. Cowie MR. Ivabradine and atrial fibrillation: What should we tell our patients? Heart 2014; 100(19):1487–8. DOI: 10.1136/heartjnl-2014-306287. http://www.ncbi.nlm.nih.gov/pubmed/24986893.

227. Kosiuk J, Oebel S, John S, et al. Ivabradine for rate control in atrial fibrillation. Int J Cardiol 2015; 179:27–8. DOI: 10.1016/j.ijcard.2014.10.062. http://www.ncbi.nlm.nih.gov/pubmed/25464400.

228. Cammarano C, Silva M, Comee M, et al. Meta-analysis of Ivabradine in Patients With Stable Coronary Artery Disease With and Without Left Ventricular Dysfunction. Clin Ther 2016; 38(2):387–95. DOI: 10.1016/j.clinthera.2015.12.018. http://www.ncbi.nlm.nih.gov/pubmed/26839043.

229. Martin RI, Pogoryelova O, Koref MS, et al. Atrial fibrillation associated with ivabradine treatment: Meta-analysis of randomised controlled trials. Heart 2014; 100(19):1506–10. DOI: 10.1136/heartjnl-2014-305482. http://www.ncbi.nlm.nih.gov/pubmed/24951486.

230. Servier Deutschland GmbH. Information für medizinisches Fachpersonal. Procoralan (Ivabradin) - Neue Kontraindikation und Empfehlungen zur Risikominimierung von kardiovaskulären Ereignissen und schweren Bradykardien. 2014 [cited: 2016-07-17]. https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2014/rhb-procoralan.pdf?__blob=publicationFile&v=3.

231. Verordnungseinschränkungen für Ivabradin (PROCORALAN) in Frankreich. Arznei-Telegramm 2016; 48(6):54.

232. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997; 336(8):525–33. http://www.ncbi.nlm.nih.gov/pubmed/9036306.

233. Hood WB, Dans AL, Guyatt GH, et al. Digitalis for treatment of heart failure in patients in sinus rhythm. Cochrane Database Syst Rev 2014(4):CD002901. DOI: 10.1002/14651858.CD002901.pub3. http://www.ncbi.nlm.nih.gov/pubmed/24771511.

234. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N. Engl. J Med 2002; 347(18):1403–11. http://www.ncbi.nlm.nih.gov/pubmed/12409542.

235. Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin: Systematic review and meta-analysis of observational and controlled trial data. BMJ 2015; 351:h4937. http://www.ncbi.nlm.nih.gov/pubmed/26374771.

236. Lewis RV, McMurray J, McDevitt DG. Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. J Cardiovasc Pharmacol 1989; 13(1):1–6. http://www.ncbi.nlm.nih.gov/pubmed/2468920.

237. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14(8):803–69. DOI: 10.1093/eurjhf/hfs105. http://www.ncbi.nlm.nih.gov/pubmed/22828712.

238. Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: A comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006; 27(2):178–86. http://www.ncbi.nlm.nih.gov/pubmed/16339157.

239. Bavendiek U, Aguirre DL, Koch A, et al. Assumption versus evidence: The case of digoxin in atrial fibrillation and heart failure. Eur Heart J 2017(0):1–5. DOI: 10.1093/eurheartj/ehw577. http://www.ncbi.nlm.nih.gov/pubmed/28065909.

240. Homma S, Thompson JL, Pullicino PM, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012; 366(20):1859–69. DOI: 10.1056/NEJMoa1202299. http://www.ncbi.nlm.nih.gov/pubmed/22551105.

241. Lip GY, Ponikowski P, Andreotti F, et al. Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Eur J Heart Fail 2012; 14(7):681–95. DOI: 10.1093/eurjhf/hfs073. http://www.ncbi.nlm.nih.gov/pubmed/22611046.

242. Lip GY, Shantsila E. Anticoagulation versus placebo for heart failure in sinus rhythm. Cochrane Database Syst Rev 2014(3):CD003336. DOI: 10.1002/14651858.CD003336.pub3. http://www.ncbi.nlm.nih.gov/pubmed/24683002.

243. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Encke A, Haas S, et al. S3-Leitlinie Prophylaxe der venösen Thromboembolie (VTE). 2015 [cited: 2016-06-30]. http://www.awmf.org/uploads/tx_szleitlinien/003-001l_S3_VTE-Prophylaxe_2015-12.pdf.

244. Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl):e691S-e736S. DOI: 10.1378/chest.11-2300. http://www.ncbi.nlm.nih.gov/pubmed/22315276.

245. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003; 362(9386):777–81. http://www.ncbi.nlm.nih.gov/pubmed/13678871.

246. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. The New England journal of medicine 2008; 359(23):2456–67. DOI: 10.1056/NEJMoa0805450. http://www.ncbi.nlm.nih.gov/pubmed/19001508.

247. Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The Aldo-DHF randomized controlled trial. JAMA 2013; 309(8):781–91. DOI: 10.1001/jama.2013.905. http://www.ncbi.nlm.nih.gov/pubmed/23443441.

248. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370(15):1383–92. DOI: 10.1056/NEJMoa1313731. http://www.ncbi.nlm.nih.gov/pubmed/24716680.

249. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial. Lancet 2012; 380(9851):1387–95. DOI: 10.1016/S0140-6736(12)61227-6. http://www.ncbi.nlm.nih.gov/pubmed/22932717.

250. Solomon SD, McMurray JJ, Anand IS, et al. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction // Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 2019:[Epub ahead of print]. DOI: 10.1056/NEJMoa1908655. http://www.ncbi.nlm.nih.gov/pubmed/31475794.

251. Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: The ancillary digitalis investigation group trial. Circulation 2006; 114(5):397–403. DOI: 10.1161/CIRCULATIONAHA.106.628347. http://www.ncbi.nlm.nih.gov/pubmed/16864724.

252. Heart Failure Clinical Research Network (HFN), Redfield MM, Chen HH, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial. JAMA 2013; 309(12):1268–77. DOI: 10.1001/jama.2013.2024. http://www.ncbi.nlm.nih.gov/pubmed/23478662.

253. Pittler MH, Guo R, Ernst E. Hawthorn extract for treating chronic heart failure. Cochrane Database Syst Rev 2008(1):CD005312. http://www.ncbi.nlm.nih.gov/pubmed/18254076.

254. Cleland JG, Coletta AP, Clark AL. Clinical trials update from the American College of Cardiology 2007: ALPHA, EVEREST, FUSION II, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet. Eur J Heart Fail 2007; 9(6-7):740–5. http://www.ncbi.nlm.nih.gov/pubmed/17481946.

255. Lalukota K, Cleland JG, Ingle L, et al. Clinical trials update from the Heart Failure Society of America: EMOTE, HERB-CHF, BEST genetic sub-study and RHYTHM-ICD. Eur J Heart Fail 2004; 6(7):953–5. http://www.ncbi.nlm.nih.gov/pubmed/15556058.

256. Holubarsch CJ, Colucci WS, Meinertz T, et al. The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: The SPICE trial. Eur J Heart Fail 2008; 10(12):1255–63. DOI: 10.1016/j.ejheart.2008.10.004. http://www.ncbi.nlm.nih.gov/pubmed/19019730.

257. Rastogi S, Pandey MM, Rawat AK. Traditional herbs: A remedy for cardiovascular disorders. Phytomedicine. 2016; 23(11):1082–9. DOI: 10.1016/j.phymed.2015.10.012. http://www.ncbi.nlm.nih.gov/pubmed/26656228.

258. Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: A long-term multicenter randomized study. Clin Investig 1993; 71(8 Suppl):S134-S136. http://www.ncbi.nlm.nih.gov/pubmed/8241697.

259. Madmani ME, Yusuf SA, Tamr AK, et al. Coenzyme Q10 for heart failure. Cochrane Database Syst Rev 2014(6):CD008684. DOI: 10.1002/14651858.CD008684.pub2. http://www.ncbi.nlm.nih.gov/pubmed/24049047.

260. Sciatti E, Lombardi C, Ravera A, et al. Nutritional Deficiency in Patients with Heart Failure. Nutrients. 2016; 8(7):422. DOI: 10.3390/nu8070442. http://www.ncbi.nlm.nih.gov/pubmed/27455314.

261. Bharani A, Ganguly A, Bhargava KD. Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure. Int J Cardiol 1995; 49(3):191–9. http://www.ncbi.nlm.nih.gov/pubmed/7649665.

262. National Collaborating Centre for Chronic Conditions (NCC-CC), National Institute for Clinical Excellence (NICE). Chronic heart failure. Management of chronic heart failure in adults in primary and secondary care. Clinical guideline No. 5. London: NICE; 2003. http://www.nice.org.uk/nicemedia/pdf/CG5NICEguideline.pdf.

263. Maulik SK, Wilson V, Seth S, et al. Clinical efficacy of water extract of stem bark of Terminalia arjuna (Roxb. ex DC.) Wight & Arn. in patients of chronic heart failure: A double-blind, randomized controlled trial. Phytomedicine. 2016; 23(11):1211–9. DOI: 10.1016/j.phymed.2016.02.007. http://www.ncbi.nlm.nih.gov/pubmed/26988798.

264. The Investigators of the Study on Propinyl-L-Carnitine in Chronic Heart Failure. Study on propionyl-L-carnitine in chronic heart failure. Eur Heart J 1999; 20(1):70–6. http://www.ncbi.nlm.nih.gov/pubmed/10075143.

265. Rizos I. Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. Am Heart J 2000; 139(2 Pt 3):S120-S123. http://www.ncbi.nlm.nih.gov/pubmed/10650325.

266. Allard ML, Jeejeebhoy KN, Sole MJ. The management of conditioned nutritional requirements in heart failure. Heart Fail Rev 2006; 11(1):75–82. http://www.ncbi.nlm.nih.gov/pubmed/16819580.

267. Krim SR, Campbell P, Lavie CJ, et al. Micronutrients in chronic heart failure. Curr Heart Fail Rep 2013; 10(1):46–53. DOI: 10.1007/s11897-012-0118-4. http://www.ncbi.nlm.nih.gov/pubmed/23070580.

268. Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2018; 7:CD003177. DOI: 10.1002/14651858.CD003177.pub3. http://www.ncbi.nlm.nih.gov/pubmed/30019766.

269. Beyranvand MR, Khalafi MK, Roshan VD, et al. Effect of taurine supplementation on exercise capacity of patients with heart failure. J Cardiol 2011; 57(3):333–7. DOI: 10.1016/j.jjcc.2011.01.007. http://www.ncbi.nlm.nih.gov/pubmed/21334852.

270. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112(12):e154-e235. http://www.ncbi.nlm.nih.gov/pubmed/16160202.

271. Ye Y, Li J, Yuan Z. Effect of antioxidant vitamin supplementation on cardiovascular outcomes: A meta-analysis of randomized controlled trials. PLoS. One. 2013; 8(2):e56803. DOI: 10.1371/journal.pone.0056803. http://www.ncbi.nlm.nih.gov/pubmed/23437244.

272. Jiang WL, Gu HB, Zhang YF, et al. Vitamin D Supplementation in the Treatment of Chronic Heart Failure: A Meta-analysis of Randomized Controlled Trials. Clin Cardiol 2016; 39(1):56–61. DOI: 10.1002/clc.22473. http://www.ncbi.nlm.nih.gov/pubmed/26415519.

273. Alon D, Stein GY, Korenfeld R, et al. Predictors and outcomes of infection-related hospital admissions of heart failure patients. PLoS. One. 2013; 8(8):e72476. DOI: 10.1371/journal.pone.0072476. http://www.ncbi.nlm.nih.gov/pubmed/24009684.

274. Opasich C, Febo O, Riccardi PG, et al. Concomitant factors of decompensation in chronic heart failure. Am. J. Cardiol. 1996; 78(3):354–7. http://www.ncbi.nlm.nih.gov/pubmed/8759821.

275. Ghali JK, Kadakia S, Cooper R, et al. Precipitating factors leading to decompensation of heart failure. Traits among urban blacks. Arch. Intern. Med 1988; 148(9):2013–6. http://www.ncbi.nlm.nih.gov/pubmed/3046541.

276. Fonarow GC, Abraham WT, Albert NM, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: Findings from OPTIMIZE-HF. Arch. Intern. Med 2008; 168(8):847–54. DOI: 10.1001/archinte.168.8.847. http://www.ncbi.nlm.nih.gov/pubmed/18443260.

277. Robert Koch Institut (RKI). Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut - 2016/2017. Epid Bull 2016(34):301–40.

278. Vardeny O, Claggett B, Udell JA, et al. Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial. JACC Heart Fail 2016; 4(2):152–8. DOI: 10.1016/j.jchf.2015.10.012. http://www.ncbi.nlm.nih.gov/pubmed/26746371.

279. Kopel E, Klempfner R, Goldenberg I. Influenza vaccine and survival in acute heart failure. Eur J Heart Fail 2014; 16(3):264–70. DOI: 10.1002/ejhf.14. http://www.ncbi.nlm.nih.gov/pubmed/24464586.

280. Mohseni H, Kiran A, Khorshidi R, et al. Influenza vaccination and risk of hospitalization in patients with heart failure: A self-controlled case series study. Eur Heart J 2017; 38(5):326–33. DOI: 10.1093/eurheartj/ehw411. http://www.ncbi.nlm.nih.gov/pubmed/27660378.

281. Modin D, Jørgensen ME, Gislason G, et al. Influenza Vaccine in Heart Failure: Cumulative Number of Vaccinations, Frequency, Timing, and Survival: A Danish Nationwide Cohort Study. Circulation 2018; 139(5):575-586. DOI: 10.1161/CIRCULATIONAHA.118.036788. http://www.ncbi.nlm.nih.gov/pubmed/30586760.

282. Pletz MW, Ewig S, Heppner HJ, et al. Stellungnahme zur Empfehlung der Pneumokokken-Impfung für Erwachsene Positionspapier der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP) und der Deutschen Gesellschaft für Geriatrie (DGG). Pneumologie 2015; 69(11):633–7. DOI: 10.1055/s-0034-1393413. http://www.ncbi.nlm.nih.gov/pubmed/26523835.

283. Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin (DGP), Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG), Deutsche Gesellschaft für Infektiologie, et al. Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie und Prävention. Update 2016. 2016 [cited: 2016-09-22]. http://www.awmf.org/uploads/tx_szleitlinien/020-020l_S3_ambulant_erworbene_Pneumonie_Behandlung_Praevention_2016-02-2.pdf.

284. Pletz MW, Rohde G, Schutte H, et al. Epidemiologie und Erreger bei ambulant erworbener Pneumonie (CAP). Dtsch Med Wochenschr 2011; 136(15):775–80. DOI: 10.1055/s-0031-1275806. http://www.ncbi.nlm.nih.gov/pubmed/21469047.

285. Moberley S, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013(1):CD000422. DOI: 10.1002/14651858.CD000422.pub3. http://www.ncbi.nlm.nih.gov/pubmed/23440780.

286. Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372(12):1114–25. DOI: 10.1056/NEJMoa1408544. http://www.ncbi.nlm.nih.gov/pubmed/25785969.

287. Luna CM, Palma I, Niederman MS, et al. The Impact of Age and Comorbidities on the Mortality of Patients of Different Age Groups Admitted with Community-acquired Pneumonia. Ann Am Thorac Soc 2016; 13(9):1519–26. DOI: 10.1513/AnnalsATS.201512-848OC. http://www.ncbi.nlm.nih.gov/pubmed/27398827.

288. Wesemann T, Nullmann H, Pflug MA, et al. Pneumonia severity, comorbidity and 1-year mortality in predominantly older adults with community-acquired pneumonia: A cohort study. BMC Infect Dis 2015; 15:2. DOI: 10.1186/s12879-014-0730-x. http://www.ncbi.nlm.nih.gov/pubmed/25566688.

289. Welte T, Kohnlein T. Global and local epidemiology of community-acquired pneumonia: The experience of the CAPNETZ Network. Semin Respir Crit Care Med 2009; 30(2):127–35. DOI: 10.1055/s-0029-1202941. http://www.ncbi.nlm.nih.gov/pubmed/19296412.

290. Ren S, Newby D, Li SC, et al. Effect of the adult pneumococcal polysaccharide vaccine on cardiovascular disease: A systematic review and meta-analysis. Open Heart 2015; 2(1):e000247. DOI: 10.1136/openhrt-2015-000247. http://www.ncbi.nlm.nih.gov/pubmed/26196020.

291. Silverman ME, Pressel MD, Brackett JC, et al. Prognostic value of the signal-averaged electrocardiogram and a prolonged QRS in ischemic and nonischemic cardiomyopathy. Am. J. Cardiol. 1995; 75(7):460–4. http://www.ncbi.nlm.nih.gov/pubmed/7863989.

292. Fried AG, Parker AB, Newton GE, et al. Electrical and hemodynamic correlates of the maximal rate of pressure increase in the human left ventricle. J Card Fail 1999; 5(1):8–16. http://www.ncbi.nlm.nih.gov/pubmed/10194655.

293. Wilensky RL, Yudelman P, Cohen AI, et al. Serial electrocardiographic changes in idiopathic dilated cardiomyopathy confirmed at necropsy. Am. J. Cardiol. 1988; 62(4):276–83. http://www.ncbi.nlm.nih.gov/pubmed/3400606.

294. Farwell D, Patel NR, Hall A, et al. How many people with heart failure are appropriate for biventricular resynchronization? Eur Heart J 2000; 21(15):1246–50. DOI: 10.1053/euhj.1999.1985. http://www.ncbi.nlm.nih.gov/pubmed/10924314.

295. Yu CM, Zhang Q, Yip GW, et al. Diastolic and systolic asynchrony in patients with diastolic heart failure: A common but ignored condition. J Am Coll Cardiol 2007; 49(1):97–105. DOI: 10.1016/j.jacc.2006.10.022. http://www.ncbi.nlm.nih.gov/pubmed/17207728.

296. Morris DA, Vaz Perez A, Blaschke F, et al. Myocardial systolic and diastolic consequences of left ventricular mechanical dyssynchrony in heart failure with normal left ventricular ejection fraction. Eur Heart J Cardiovasc Imaging 2012; 13(7):556–67. DOI: 10.1093/ehjci/jes042. http://www.ncbi.nlm.nih.gov/pubmed/22383372.

297. Santos AB, Kraigher-Krainer E, Bello N, et al. Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. Eur Heart J 2014; 35(1):42–7. DOI: 10.1093/eurheartj/eht427. http://www.ncbi.nlm.nih.gov/pubmed/24164863.

298. Shah AM, Solomon SD. Mechanical Dyssynchrony: A Risk Factor but not a Target. Eur Heart J 2016; 37(1):60–2. DOI: 10.1093/eurheartj/ehv458. http://www.ncbi.nlm.nih.gov/pubmed/26324539.

299. Institut für Qualitätssicherung und Transparenz im Gesundheitswesen (IQTIG). Herzschrittmacher-Implantation. Qualitätsindikatoren. Bundesauswertung zum Erfassungsjahr 2015. 2016 [cited: 2019-10-01]. https://iqtig.org/downloads/auswertung/2015/09n1hsmimpl/QSKH_09n1-HSM-IMPL_2015_BUAW_V02_2016-07-07.pdf.

300. Institut für Qualitätssicherung und Transparenz im Gesundheitswesen (IQTIG). Implantierbare Defibrillatoren-Implantation. Qualitätsindikatoren. Bundesauswertung zum Erfassungsjahr 2015. 2016 [cited: 2019-10-01]. https://iqtig.org/downloads/auswertung/2015/09n4defiimpl/QSKH_09n4-DEFI-IMPL_2015_BUAW_V02_2016-07-07.pdf.

301. Sohaib SM, Finegold JA, Nijjer SS, et al. Opportunity to increase life span in narrow QRS cardiac resynchronization therapy recipients by deactivating ventricular pacing: Evidence from randomized controlled trials. JACC Heart Fail 2015; 3(4):327–36. DOI: 10.1016/j.jchf.2014.11.007. http://www.ncbi.nlm.nih.gov/pubmed/25770400.

302. Cleland JG, Mareev Y, Linde C. Reflections on EchoCRT: Sound guidance on QRS duration and morphology for CRT? Eur Heart J 2015; 36(30):1948–51. DOI: 10.1093/eurheartj/ehv264. http://www.ncbi.nlm.nih.gov/pubmed/26180135.

303. Woods B, Hawkins N, Mealing S, et al. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. Heart 2015; 101(22):1800–6. DOI: 10.1136/heartjnl-2015-307634. http://www.ncbi.nlm.nih.gov/pubmed/26269413.

304. Zusterzeel R, Selzman KA, Sanders WE, et al. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patient-level data. JAMA Intern Med 2014; 174(8):1340–8. DOI: 10.1001/jamainternmed.2014.2717. http://www.ncbi.nlm.nih.gov/pubmed/25090172.

305. Linde C, Stahlberg M, Benson L, et al. Gender, underutilization of cardiac resynchronization therapy, and prognostic impact of QRS prolongation and left bundle branch block in heart failure. Europace 2015; 17(3):424–31. DOI: 10.1093/europace/euu205. http://www.ncbi.nlm.nih.gov/pubmed/25164429.

306. Cleland JG, Abraham WT, Linde C, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J 2013; 34(46):3547–56. DOI: 10.1093/eurheartj/eht290. http://www.ncbi.nlm.nih.gov/pubmed/23900696.

307. Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J 2013; 34(29):2281–329. DOI: 10.1093/eurheartj/eht150. http://www.ncbi.nlm.nih.gov/pubmed/23801822.

308. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J Med 2005; 352(15):1539–49. http://www.ncbi.nlm.nih.gov/pubmed/15753115.

309. Cleland JG, Daubert JC, Erdmann E, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 2006; 27(16):1928–32. DOI: 10.1093/eurheartj/ehl099. http://www.ncbi.nlm.nih.gov/pubmed/16782715.

310. Cleland JG, Calvert MJ, Verboven Y, et al. Effects of cardiac resynchronization therapy on long-term quality of life: An analysis from the CArdiac Resynchronisation-Heart Failure (CARE-HF) study. Am Heart J 2009; 157(3):457–66. DOI: 10.1016/j.ahj.2008.11.006. http://www.ncbi.nlm.nih.gov/pubmed/19249415.

311. Cleland JG, Freemantle N, Erdmann E, et al. Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization-Heart Failure (CARE-HF) trial. Eur J Heart Fail 2012; 14(6):628–34. DOI: 10.1093/eurjhf/hfs055. http://www.ncbi.nlm.nih.gov/pubmed/22552183.

312. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N. Engl. J Med 2004; 350(21):2140–50. http://www.ncbi.nlm.nih.gov/pubmed/15152059.

313. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. The New England journal of medicine 2009; 361(14):1329–38. DOI: 10.1056/NEJMoa0906431. http://www.ncbi.nlm.nih.gov/pubmed/19723701.

314. Goldenberg I, Kutyifa V, Klein HU, et al. Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med 2014; 370(18):1694–701. DOI: 10.1056/NEJMoa1401426. http://www.ncbi.nlm.nih.gov/pubmed/24678999.

315. Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N. Engl. J Med 2010; 363(25):2385–95. DOI: 10.1056/NEJMoa1009540. http://www.ncbi.nlm.nih.gov/pubmed/21073365.

316. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344(12):873–80. http://www.ncbi.nlm.nih.gov/pubmed/11259720.

317. Leclercq C, Walker S, Linde C, et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J 2002; 23(22):1780–7. http://www.ncbi.nlm.nih.gov/pubmed/12419298.

318. Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in congestive heart failure: Results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 2002; 40(1):111–8. http://www.ncbi.nlm.nih.gov/pubmed/12103264.

319. Daubert C, Gold MR, Abraham WT, et al. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: Insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol 2009; 54(20):1837–46. DOI: 10.1016/j.jacc.2009.08.011. http://www.ncbi.nlm.nih.gov/pubmed/19800193.

320. Linde C, Abraham WT, Gold MR, et al. Randomized Trial of Cardiac Resynchronization in Mildly Symptomatic Heart Failure Patients and in Asymptomatic Patients With Left Ventricular Dysfunction and Previous Heart Failure Symptoms. J Am Coll Cardiol 2008; 52(23):1834–43. http://www.ncbi.nlm.nih.gov/pubmed/19038680.

321. Linde C, Gold MR, Abraham WT, et al. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J 2013; 34(33):2592–9. DOI: 10.1093/eurheartj/eht160. http://www.ncbi.nlm.nih.gov/pubmed/23641006.

322. Ruschitzka F, Abraham WT, Singh JP, et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med 2013; 369(15):1395–405. DOI: 10.1056/NEJMoa1306687. http://www.ncbi.nlm.nih.gov/pubmed/23998714.

323. Steffel J, Robertson M, Singh JP, et al. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: A subgroup analysis of the EchoCRT trial. Eur Heart J 2015; 36(30):1983–9. DOI: 10.1093/eurheartj/ehv242. http://www.ncbi.nlm.nih.gov/pubmed/26009595.

324. Gervais R, Leclercq C, Shankar A, et al. Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: A sub-analysis of the CARE-HF trial. Eur J Heart Fail 2009; 11(7):699–705. DOI: 10.1093/eurjhf/hfp074. http://www.ncbi.nlm.nih.gov/pubmed/19505883.

325. Sipahi I, Chou JC, Hyden M, et al. Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: Meta-analysis of randomized controlled trials. Am Heart J 2012; 163(2):260–7. DOI: 10.1016/j.ahj.2011.11.014. http://www.ncbi.nlm.nih.gov/pubmed/22305845.

326. Birnie DH, Ha A, Higginson L, et al. Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: Results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail 2013; 6(6):1190–8. DOI: 10.1161/CIRCHEARTFAILURE.113.000380. http://www.ncbi.nlm.nih.gov/pubmed/23995437.

327. Gold MR, Thebault C, Linde C, et al. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: Results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study. Circulation 2012; 126(7):822–9. DOI: 10.1161/CIRCULATIONAHA.112.097709. http://www.ncbi.nlm.nih.gov/pubmed/22781424.

328. Kobe J, Andresen D, Maier S, et al. Complications and 1-year benefit of cardiac resynchronization therapy in patients over 75 years of age - Insights from the German Device Registry. Int J Cardiol 2016; 228:784–9. DOI: 10.1016/j.ijcard.2016.11.212. http://www.ncbi.nlm.nih.gov/pubmed/27898337.

329. Heidenreich PA, Tsai V, Bao H, et al. Does Age Influence Cardiac Resynchronization Therapy Use and Outcome? JACC Heart Fail 2015; 3(6):497–504. DOI: 10.1016/j.jchf.2015.01.012. http://www.ncbi.nlm.nih.gov/pubmed/25982109.

330. Brignole M, Botto G, Mont L, et al. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: A randomized trial. Eur Heart J 2011; 32(19):2420–9. DOI: 10.1093/eurheartj/ehr162. http://www.ncbi.nlm.nih.gov/pubmed/21606084.

331. Upadhyay GA, Choudhry NK, Auricchio A, et al. Cardiac resynchronization in patients with atrial fibrillation: A meta-analysis of prospective cohort studies. J Am Coll Cardiol 2008; 52(15):1239–46. http://www.ncbi.nlm.nih.gov/pubmed/18926327.

332. Gasparini M, Leclercq C, Lunati M, et al. Cardiac resynchronization therapy in patients with atrial fibrillation: The CERTIFY study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). JACC Heart Fail 2013; 1(6):500–7. DOI: 10.1016/j.jchf.2013.06.003. http://www.ncbi.nlm.nih.gov/pubmed/24622002.

333. Lopes C, Pereira T, Barra S. Cardiac resynchronization therapy in patients with atrial fibrillation: A meta-analysis. Rev Port. Cardiol 2014; 33(11):717–25. DOI: 10.1016/j.repc.2014.05.008. http://www.ncbi.nlm.nih.gov/pubmed/25457476.

334. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37(38):2893–962. DOI: 10.1093/eurheartj/ehw210. http://www.ncbi.nlm.nih.gov/pubmed/27567408.

335. Doshi RN, Daoud EG, Fellows C, et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol. 2005; 16(11):1160–5. http://www.ncbi.nlm.nih.gov/pubmed/16302897.

336. Stavrakis S, Garabelli P, Reynolds DW. Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial fibrillation: A meta-analysis. Europace 2012; 14(10):1490–7. DOI: 10.1093/europace/eus193. http://www.ncbi.nlm.nih.gov/pubmed/22696519.

337. Curtis AB, Worley SJ, Adamson PB, et al. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med 2013; 368(17):1585–93. DOI: 10.1056/NEJMoa1210356. http://www.ncbi.nlm.nih.gov/pubmed/23614585.

338. Funck RC, Blanc JJ, Mueller HH, et al. Biventricular stimulation to prevent cardiac desynchronization: Rationale, design, and endpoints of the ‚Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization (BioPace)‘ study. Europace 2006; 8(8):629–35. DOI: 10.1093/europace/eul075. http://www.ncbi.nlm.nih.gov/pubmed/16864616.

339. Blanc JJ. Biopace Trial Preliminary Results. ESC Congress 2014: Presentation. 2014 [cited: 2017-01-30]. http://clinicaltrialresults.org/Slides/TCT%202014/Blanc_Biopace.pdf.

340. Gage RM, Burns KV, Bank AJ. Echocardiographic and clinical response to cardiac resynchronization therapy in heart failure patients with and without previous right ventricular pacing. Eur J Heart Fail 2014; 16(11):1199–205. DOI: 10.1002/ejhf.143. http://www.ncbi.nlm.nih.gov/pubmed/25132044.

341. Kirkfeldt RE, Johansen JB, Nohr EA, et al. Complications after cardiac implantable electronic device implantations: An analysis of a complete, nationwide cohort in Denmark. Eur Heart J 2014; 35(18):1186–94. DOI: 10.1093/eurheartj/eht511. http://www.ncbi.nlm.nih.gov/pubmed/24347317.

342. Bogale N, Priori S, Gitt A, et al. The European cardiac resynchronization therapy survey: Patient selection and implantation practice vary according to centre volume. Europace 2011; 13(10):1445–53. DOI: 10.1093/europace/eur173. http://www.ncbi.nlm.nih.gov/pubmed/21712274.

343. Freeman JV, Wang Y, Curtis JP, et al. Physician procedure volume and complications of cardioverter-defibrillator implantation. Circulation 2012; 125(1):57–64. DOI: 10.1161/CIRCULATIONAHA.111.046995. http://www.ncbi.nlm.nih.gov/pubmed/22095828.

344. Poole JE, Gleva MJ, Mela T, et al. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: Results from the REPLACE registry. Circulation 2010; 122(16):1553–61. DOI: 10.1161/CIRCULATIONAHA.110.976076. http://www.ncbi.nlm.nih.gov/pubmed/20921437.

345. Jung W, Andresen D, Block M, et al. Leitlinien zur Implantation von Defibrillatoren. Clin Res Cardiol 2006; 95(12):696–708. http://www.ncbi.nlm.nih.gov/pubmed/17103126.

346. Deutsche Herzstiftung. Deutscher Herzbericht 2016. 28. Sektorenübergreifende Versorgungsanalyse zur Kardiologie und Herzchirurgie in Deutschland. Frankfurt/Main: Deutsche Herzstiftung; 2016.

347. Green AR, Boyd CM, Rickard J, et al. Attitudes of older adults with serious competing health risks toward their implantable cardioverter-defibrillators: A pilot study. BMC Geriatr 2015; 15:173. DOI: 10.1186/s12877-015-0173-2. http://www.ncbi.nlm.nih.gov/pubmed/26700296.

348. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102(7):748–54. http://www.ncbi.nlm.nih.gov/pubmed/10942742.

349. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101(11):1297–302. http://www.ncbi.nlm.nih.gov/pubmed/10725290.

350. Zipes DP, Wyse DG, Friedman PL. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997; 337(22):1576–83. DOI: 10.1056/NEJM199711273372202. http://www.ncbi.nlm.nih.gov/pubmed/9411221.

351. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg Canadian Implantable Defibrillator Study. Eur Heart J 2000; 21(24):2071–8. http://www.ncbi.nlm.nih.gov/pubmed/11102258.

352. McAlister FA, Ezekowitz J, Dryden DM, et al. Cardiac resynchronization therapy and implantable cardiac defibrillators in left ventricular systolic dysfunction. Evid Rep Technol Assess (Full Rep) 2007(152):1–199. http://www.ncbi.nlm.nih.gov/pubmed/17764218.

353. Betts TR, Sadarmin PP, Tomlinson DR, et al. Absolute risk reduction in total mortality with implantable cardioverter defibrillators: Analysis of primary and secondary prevention trial data to aid risk/benefit analysis. Europace 2013; 15(6):813–9. DOI: 10.1093/europace/eus427. http://www.ncbi.nlm.nih.gov/pubmed/23365069.

354. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J Med 2002; 346(12):877–83. http://www.ncbi.nlm.nih.gov/pubmed/11907286.

355. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J Med 2005; 352(3):225–37. http://www.ncbi.nlm.nih.gov/pubmed/15659722.

356. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N. Engl. J Med 2004; 351(24):2481–8. http://www.ncbi.nlm.nih.gov/pubmed/15590950.

357. Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. N. Engl. J Med 2009; 361(15):1427–36. http://www.ncbi.nlm.nih.gov/pubmed/19812399.

358. Kober L, Thune JJ, Nielsen JC, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med 2016; 375(13):1221–30. DOI: 10.1056/NEJMoa1608029. http://www.ncbi.nlm.nih.gov/pubmed/27571011.

359. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335(26):1933–40. http://www.ncbi.nlm.nih.gov/pubmed/8960472.

360. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341(25):1882–90. DOI: 10.1056/NEJM199912163412503. http://www.ncbi.nlm.nih.gov/pubmed/10601507.

361. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N. Engl. J Med 2004; 350(21):2151–8. http://www.ncbi.nlm.nih.gov/pubmed/15152060.

362. Chen CY, Stevenson LW, Stewart GC, et al. Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: Cohort study of older patients with heart failure. BMJ 2015; 351:h3529. http://www.ncbi.nlm.nih.gov/pubmed/26174233.

363. Green AR, Leff B, Wang Y, et al. Geriatric Conditions in Patients Undergoing Defibrillator Implantation for Prevention of Sudden Cardiac Death: Prevalence and Impact on Mortality. Circ Cardiovasc Qual Outcomes 2016; 9(1):23–30. DOI: 10.1161/CIRCOUTCOMES.115.002053. http://www.ncbi.nlm.nih.gov/pubmed/26715650.

364. Steinberg BA, Al-Khatib SM, Edwards R, et al. Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: Results from a combined analysis of 4 randomized clinical trials. JACC Heart Fail 2014; 2(6):623–9. DOI: 10.1016/j.jchf.2014.06.007. http://www.ncbi.nlm.nih.gov/pubmed/25306452.

365. Raphael CE, Finegold JA, Barron AJ, et al. The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: Who benefits the most? Eur Heart J 2015; 36(26):1676–88. DOI: 10.1093/eurheartj/ehv102. http://www.ncbi.nlm.nih.gov/pubmed/25908776.

366. Miller RJ, Howlett JG, Exner DV, et al. Baseline Functional Class and Therapeutic Efficacy of Common Heart Failure Interventions: A Systematic Review and Meta-analysis. Can J Cardiol 2015; 31(6):792–9. DOI: 10.1016/j.cjca.2014.12.031. http://www.ncbi.nlm.nih.gov/pubmed/26022990.

367. Hess PL, Al-Khatib SM, Han JY, et al. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: Does age matter? An analysis of pooled data from 5 clinical trials. Circ Cardiovasc Qual Outcomes 2015; 8(2):179–86. DOI: 10.1161/CIRCOUTCOMES.114.001306. http://www.ncbi.nlm.nih.gov/pubmed/25669833.

368. Merchant FM, Jones P, Wehrenberg S, et al. Incidence of defibrillator shocks after elective generator exchange following uneventful first battery life. J Am Heart Assoc 2014; 3(6):e001289. DOI: 10.1161/JAHA.114.001289. http://www.ncbi.nlm.nih.gov/pubmed/25385346.

369. Yap SC, Schaer BA, Bhagwandien RE, et al. Evaluation of the need of elective implantable cardioverter-defibrillator generator replacement in primary prevention patients without prior appropriate ICD therapy. Heart 2014; 100(15):1188–92. DOI: 10.1136/heartjnl-2014-305535. http://www.ncbi.nlm.nih.gov/pubmed/24993502.

370. Erkapic D, Sperzel J, Stiller S, et al. Long-term benefit of implantable cardioverter/defibrillator therapy after elective device replacement: Results of the INcidence free SUrvival after ICD REplacement (INSURE) trial—a prospective multicentre study. Eur Heart J 2013; 34(2):130–7. DOI: 10.1093/eurheartj/ehs177. http://www.ncbi.nlm.nih.gov/pubmed/22771679.

371. Alsheikh-Ali AA, Homer M, Maddukuri PV, et al. Time-dependence of appropriate implantable defibrillator therapy in patients with ischemic cardiomyopathy. J Cardiovasc Electrophysiol. 2008; 19(8):784–9. DOI: 10.1111/j.1540-8167.2008.01111.x. http://www.ncbi.nlm.nih.gov/pubmed/18284493.

372. Kini V, Soufi MK, Deo R, et al. Appropriateness of primary prevention implantable cardioverter-defibrillators at the time of generator replacement: Are indications still met? J Am Coll Cardiol 2014; 63(22):2388–94. DOI: 10.1016/j.jacc.2014.03.025. http://www.ncbi.nlm.nih.gov/pubmed/24727249.

373. Institut für Qualitätssicherung und Transparenz im Gesundheitswesen (IQTIG). Implantierbare Defibrillatoren-Aggregatwechsel. Indikatoren 2015. Bundesauswertung zum Erfassungsjahr 2015. 2016 [cited: 2019-10-01]. https://iqtig.org/downloads/auswertung/2015/09n5defiaggw/QSKH_09n5-DEFI-AGGW_2015_QIDB_V01_2016-05-04.pdf.

374. Hu ZY, Zhang J, Xu ZT, et al. Efficiencies and Complications of Dual Chamber versus Single Chamber Implantable Cardioverter Defibrillators in Secondary Sudden Cardiac Death Prevention: A Meta-analysis. Heart Lung Circ 2016; 25(2):148–54. DOI: 10.1016/j.hlc.2015.07.008. http://www.ncbi.nlm.nih.gov/pubmed/26338316.

375. Chen BW, Liu Q, Wang X, et al. Are dual-chamber implantable cardioverter-defibrillators really better than single-chamber ones? A systematic review and meta-analysis. J Interv Card Electrophysiol. 2014; 39(3):273–80. DOI: 10.1007/s10840-014-9873-3. http://www.ncbi.nlm.nih.gov/pubmed/24532113.

376. Goncalves J, Pereira T. Inappropriate shocks in patients with ICDs: Single chamber versus dual chamber. Arq Bras Cardiol 2013; 101(2):141–8. DOI: 10.5935/abc.20130125. http://www.ncbi.nlm.nih.gov/pubmed/23821405.

377. Schwab JO, Bänsch D, Israel C, et al. Stellungnahme zum Einsatz des tragbaren Kardioverter/Defibrillators. Der Kardiologe 2015; 9(2):165–70. DOI: 10.1007/s12181-015-0651-y.

378. Ettinger S, Stanak M, Huic M, et al. Tragbare Kardioverter Defibrillator Therapie zur Primär- und Sekundärprävention von plötzlichem Herzstillstand Deutsche Zusammenfassung des EUnetHTA-Berichts. 2016 (Decision Support Document; 103) [cited: 2017-07-17]. http://eprints.hta.lbg.ac.at/1109/1/DSD_103.pdf.

379. Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med 2010; 363(1):36–44. DOI: 10.1056/NEJMoa0909545. http://www.ncbi.nlm.nih.gov/pubmed/20463331.

380. Aziz S, Leon AR, El-Chami MF. The subcutaneous defibrillator: A review of the literature. J Am Coll Cardiol 2014; 63(15):1473–9. DOI: 10.1016/j.jacc.2014.01.018. http://www.ncbi.nlm.nih.gov/pubmed/24530663.

381. Olde Nordkamp LR, Knops RE, Bardy GH, et al. Rationale and design of the PRAETORIAN trial: A Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy. Am Heart J 2012; 163(5):753–60. DOI: 10.1016/j.ahj.2012.02.012. http://www.ncbi.nlm.nih.gov/pubmed/22607851.

382. Burke MC, Gold MR, Knight BP, et al. Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry. J Am Coll Cardiol 2015; 65(16):1605–15. DOI: 10.1016/j.jacc.2015.02.047. http://www.ncbi.nlm.nih.gov/pubmed/25908064.

383. Boveda S, Lenarczyk R, Haugaa K, et al. Implantation of subcutaneous implantable cardioverter defibrillators in Europe: Results of the European Heart Rhythm Association survey. Europace 2016; 18(9):1434–9. DOI: 10.1093/europace/euw258. http://www.ncbi.nlm.nih.gov/pubmed/27582309.

384. Ascoeta MS, Marijon E, Defaye P, et al. Impact of early complications on outcomes in patients with implantable cardioverter-defibrillator for primary prevention. Heart Rhythm 2016; 13(5):1045–51. DOI: 10.1016/j.hrthm.2015.12.046. http://www.ncbi.nlm.nih.gov/pubmed/26749313.

385. van der Heijden AC, Borleffs CJ, Buiten MS, et al. The clinical course of patients with implantable cardioverter-defibrillators: Extended experience on clinical outcome, device replacements, and device-related complications. Heart Rhythm 2015; 12(6):1169–76. DOI: 10.1016/j.hrthm.2015.02.035. http://www.ncbi.nlm.nih.gov/pubmed/25749138.

386. Deutsche Herzstiftung. Deutscher Herzbericht 2015. 27. Sektorenübergreifende Versorgungsanalyse zur Kardiologie und Herzchirurgie in Deutschland. Frankfurt/Main: Deutsche Herzstiftung; 2015.

387. Ho C, Li H, Noorani H, et al. Implantable cardiac defibrillators for primary prevention of sudden cardiac death in high risk patients: A meta-analysis of clinical efficacy, and a review of cost-effectiveness and psychosocial issues. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2007 (Technology report; 81). http://www.cadth.ca/media/pdf/332_ICD_tr_e.pdf.

388. Ladwig KH, Lederbogen F, Albus C, et al. Positionspapier zur Bedeutung psychosozialer Faktoren in der Kardiologie. Update 2013. Der Kardiologe 2013; 7(1):7–27. DOI: 10.1007/s12181-012-0478-8.

389. Lozano I, Bocchiardo M, Achtelik M, et al. Impact of biventricular pacing on mortality in a randomized crossover study of patients with heart failure and ventricular arrhythmias. Pacing Clin Electrophysiol. 2000; 23(11 Pt 2):1711–2. http://www.ncbi.nlm.nih.gov/pubmed/11139906.

390. Schuchert A, Muto C, Maounis T, et al. Lead complications, device infections, and clinical outcomes in the first year after implantation of cardiac resynchronization therapy-defibrillator and cardiac resynchronization therapy-pacemaker. Europace 2013; 15(1):71–6. DOI: 10.1093/europace/eus247. http://www.ncbi.nlm.nih.gov/pubmed/22927665.

391. Munir MB, Althouse AD, Rijal S, et al. Clinical Characteristics and Outcomes of Older Cardiac Resynchronization Therapy Recipients Using a Pacemaker versus a Defibrillator. J Cardiovasc Electrophysiol. 2016; 27(6):730–4. DOI: 10.1111/jce.12951. http://www.ncbi.nlm.nih.gov/pubmed/26856440.

392. Barra S, Providencia R, Tang A, et al. Importance of Implantable Cardioverter-Defibrillator Back-Up in Cardiac Resynchronization Therapy Recipients: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2015; 4(11):e002539. DOI: 10.1161/JAHA.115.002539. http://www.ncbi.nlm.nih.gov/pubmed/26546574.

393. Dickstein K, Bogale N, Priori S, et al. The European cardiac resynchronization therapy survey. Eur Heart J 2009; 30(20):2450–60. DOI: 10.1093/eurheartj/ehp359. http://www.ncbi.nlm.nih.gov/pubmed/19723694.

394. Lam SK, Owen A. Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials. BMJ 2007; 335(7626):925. http://www.ncbi.nlm.nih.gov/pubmed/17932160.

395. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische KHK - Langfassung, 4. Auflage. Version 1. 2016 [cited: 2017-06-26]. DOI: 10.6101/AZQ/000267. http://doi.org/10.6101/AZQ/000267.

396. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35(37):2541–619. DOI: 10.1093/eurheartj/ehu278. http://www.ncbi.nlm.nih.gov/pubmed/25173339.

397. Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011; 364(17):1607–16. http://www.ncbi.nlm.nih.gov/pubmed/21463150.

398. Velazquez EJ, Lee KL, Jones RH, et al. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. N Engl J Med 2016; 374(16):1511–20. DOI: 10.1056/NEJMoa1602001. http://www.ncbi.nlm.nih.gov/pubmed/27040723.

399. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997; 349(9058):1050–3. http://www.ncbi.nlm.nih.gov/pubmed/9107242.

400. Wrobel K, Stevens SR, Jones RH, et al. Influence of Baseline Characteristics, Operative Conduct, and Postoperative Course on 30-Day Outcomes of Coronary Artery Bypass Grafting Among Patients With Left Ventricular Dysfunction: Results From the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. Circulation 2015; 132(8):720–30. DOI: 10.1161/CIRCULATIONAHA.114.014932. http://www.ncbi.nlm.nih.gov/pubmed/26304663.

401. M AN, Aggarwal S, Reddy YN, et al. Surgical Repair of Moderate Ischemic Mitral Regurgitation-A Systematic Review and Meta-analysis. Thorac Cardiovasc Surg 2017; 65(6):447–56. DOI: 10.1055/s-0036-1598012. http://www.ncbi.nlm.nih.gov/pubmed/28109210.

402. Michler RE, Smith PK, Parides MK, et al. Two-Year Outcomes of Surgical Treatment of Moderate Ischemic Mitral Regurgitation. N Engl J Med 2016; 374(20):1932–41. DOI: 10.1056/NEJMoa1602003. http://www.ncbi.nlm.nih.gov/pubmed/27040451.

403. Mihos CG, Larrauri-Reyes M, Santana O. A Meta-Analysis of Ring Annuloplasty Versus Combined Ring Annuloplasty and Subvalvular Repair for Moderate-to-Severe Functional Mitral Regurgitation. J Card Surg 2016; 31(1):31–7. DOI: 10.1111/jocs.12662. http://www.ncbi.nlm.nih.gov/pubmed/26626776.

404. Nappi F, Lusini M, Spadaccio C, et al. Papillary Muscle Approximation Versus Restrictive Annuloplasty Alone for Severe Ischemic Mitral Regurgitation. J Am Coll Cardiol 2016; 67(20):2334–46. DOI: 10.1016/j.jacc.2016.03.478. http://www.ncbi.nlm.nih.gov/pubmed/27199056.

405. Takagi H, Umemoto T. Similar Survival After Repair vs Replacement for Ischemic Mitral Regurgitation. Semin. Thorac. Cardiovasc. Surg. 2016; 28(4):748–56. DOI: 10.1053/j.semtcvs.2016.09.001. http://www.ncbi.nlm.nih.gov/pubmed/28417860.

406. Acker MA, Parides MK, Perrault LP, et al. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med 2014; 370(1):23–32. DOI: 10.1056/NEJMoa1312808. http://www.ncbi.nlm.nih.gov/pubmed/24245543.

407. Goldstein D, Moskowitz AJ, Gelijns AC, et al. Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. N Engl J Med 2016; 374(4):344–53. DOI: 10.1056/NEJMoa1512913. http://www.ncbi.nlm.nih.gov/pubmed/26550689.

408. Institut für Qualitätssicherung und Transparenz im Gesundheitswesen (IQTIG). Herzunterstützungssysteme/Kunstherzen. Qualitätsindikatoren. Bundesauswertung zum Erfassungsjahr 2015. 2016 [cited: 2019-10-01]. https://iqtig.org/downloads/auswertung/2015/htxmmku/QSKH_HTXM-MKU_2015_BUAW_V02_2016-07-07.pdf.

409. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001; 345(20):1435–43. http://www.ncbi.nlm.nih.gov/pubmed/11794191.

410. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009; 361(23):2241–51. DOI: 10.1056/NEJMoa0909938. http://www.ncbi.nlm.nih.gov/pubmed/19920051.

411. Gillespie F, Abraha I, Amicosante AM, et al. Implantable LVAD (Left Ventricular Assist Device) in addition to guideline directed medical therapy (GDMT) in end stage heart failure. HTA Report. 2015 [cited: 2019-10-01]. http://www.salute.gov.it/imgs/C_17_ReportDispositivi_13_documentoInglese_inglese_itemName_0_documentoENG.pdf.

412. Neyt M, Leroy R, Devos C, et al. Left ventricular assist devices in the treatment of end-stage heart failure. 2016 [cited: 2017-01-10]. http://www.kce.fgov.be/sites/default/files/page_documents/KCE_264_LVAD_report.pdf.

413. Health Quality Ontario (HQO). Left ventricular assist devices for destination therapy: A health technology assessment. 2016 [cited: 2017-01-10]. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4761917/pdf/ohtas-16-1.pdf.

414. Sutcliffe P, Connock M, Pulikottil-Jacob R, et al. Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: Systematic review and cost-effectiveness model. Health Technol Assess 2013; 17(53):1-vi. DOI: 10.3310/hta17530. http://www.ncbi.nlm.nih.gov/pubmed/24280231.

415. Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs). Quarterly Statistical Report. 2016 Q3. 2016 [cited: 2017-01-30]. http://www.uab.edu/medicine/intermacs/images/Federal_Quarterly_Report/Federal_Partners_Report_2016_Q3.pdf.

416. Kirklin JK, Cantor R, Mohacsi P, et al. First Annual IMACS Report: A global International Society for Heart and Lung Transplantation Registry for Mechanical Circulatory Support. J Heart Lung Transplant 2016; 35(4):407–12. DOI: 10.1016/j.healun.2016.01.002. http://www.ncbi.nlm.nih.gov/pubmed/26922275.

417. Lund LH, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Heart Transplantation Report--2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant 2015; 34(10):1244–54. DOI: 10.1016/j.healun.2015.08.003. http://www.ncbi.nlm.nih.gov/pubmed/26454738.

418. Mehra MR, Naka Y, Uriel N, et al. A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure. N Engl J Med 2017; 376(5):440–50. DOI: 10.1056/NEJMoa1610426. http://www.ncbi.nlm.nih.gov/pubmed/27959709.

419. International Society for Heart & Lung Transplantation (ISHLT). ISHLT Transplant Registry Quarterly Reports for Heart in Europe. Survival Rates for Transplants performed between October 1, 2011 and September 30, 2015. 2016 [cited: 2017-01-30]. https://ishltregistries.org/registries/quarterlyDataReport.asp.

420. Ständige Impfkommission am Robert Koch Institut (STIKO). Mitteilung der Ständigen Impfkommission am Robert Koch-Institut: Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut. Epidemiologisches Bulletin / Nr. 30. 2005 [cited: 2017-05-10]. http://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2005/Ausgabenlinks/30_05.pdf?__blob=publicationFile.

421. Ballout A, Goffin E, Yombi JC, et al. Vaccinations for adult solid organ transplant recipient: Current recommendations. Transplant. Proc 2005; 37(6):2826–7. http://www.ncbi.nlm.nih.gov/pubmed/16182821.

422. Westaby S. Non-transplant surgery for heart failure. Heart 2000; 83(5):603–10. http://www.ncbi.nlm.nih.gov/pubmed/10768919.

423. Dor V, Sabatier M, Di Donato M, et al. Efficacy of endoventricular patch plasty in large postinfarction akinetic scar and severe left ventricular dysfunction: Comparison with a series of large dyskinetic scars. J Thorac Cardiovasc Surg 1998; 116(1):50–9. http://www.ncbi.nlm.nih.gov/pubmed/9671897.

424. Menicanti L, Di Donato M. Left Ventricular Restoration: How Important is the Surgical Treatment of Ischemic Heart Failure Trial? Heart Fail Clin 2007; 3(2):237–43. http://www.ncbi.nlm.nih.gov/pubmed/17643924.

425. Buckberg GD. Defining the relationship between akinesia and dyskinesia and the cause of left ventricular failure after anterior infarction and reversal of remodeling to restoration. J Thorac Cardiovasc Surg 1998; 116(1):47–9. http://www.ncbi.nlm.nih.gov/pubmed/9671896.

426. Westaby S. Surgery for heart failure: Now something for everyone? Heart Fail Clin 2007; 3(2):139–57. http://www.ncbi.nlm.nih.gov/pubmed/17643919.

427. Large S. Surgery for heart failure. Heart 2007; 93(3):392–402. http://www.ncbi.nlm.nih.gov/pubmed/17322524.

428. Jones RH, Velazquez EJ, Michler RE, et al. Coronary bypass surgery with or without surgical ventricular reconstruction. N. Engl. J Med 2009; 360(17):1705–17. http://www.ncbi.nlm.nih.gov/pubmed/19329820.

429. Michler RE, Rouleau JL, Al-Khalidi HR, et al. Insights from the STICH trial: Change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction. J Thorac Cardiovasc Surg 2013; 146(5):1139–45. DOI: 10.1016/j.jtcvs.2012.09.007. http://www.ncbi.nlm.nih.gov/pubmed/23111018.

430. Kuck KH, Bordachar P, Borggrefe M, et al. New devices in heart failure: An European Heart Rhythm Association report: developed by the European Heart Rhythm Association; endorsed by the Heart Failure Association. Europace 2014; 16(1):109–28. DOI: 10.1093/europace/eut311. http://www.ncbi.nlm.nih.gov/pubmed/24265466.

431. Singh JP, Kandala J, Camm AJ. Non-pharmacological modulation of the autonomic tone to treat heart failure. Eur Heart J 2014; 35(2):77–85. DOI: 10.1093/eurheartj/eht436. http://www.ncbi.nlm.nih.gov/pubmed/24174128.

432. Abraham WT, Zile MR, Weaver FA, et al. Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. JACC Heart Fail 2015; 3(6):487–96. DOI: 10.1016/j.jchf.2015.02.006. http://www.ncbi.nlm.nih.gov/pubmed/25982108.

433. Kadish A, Nademanee K, Volosin K, et al. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. Am Heart J 2011; 161(2):329–37. DOI: 10.1016/j.ahj.2010.10.025. http://www.ncbi.nlm.nih.gov/pubmed/21315216.

434. Borggrefe MM, Lawo T, Butter C, et al. Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J 2008; 29(8):1019–28. DOI: 10.1093/eurheartj/ehn020. http://www.ncbi.nlm.nih.gov/pubmed/18270213.

435. Zannad F, Ferrari GM de, Tuinenburg AE, et al. Chronic vagal stimulation for the treatment of low ejection fraction heart failure: Results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. Eur Heart J 2015; 36(7):425–33. DOI: 10.1093/eurheartj/ehu345. http://www.ncbi.nlm.nih.gov/pubmed/25176942.

436. Fromme EK, Stewart TL, Jeppesen M, et al. Adverse experiences with implantable defibrillators in Oregon hospices. Am J Hosp Palliat Care 2011; 28(5):304–9. DOI: 10.1177/1049909110390505. http://www.ncbi.nlm.nih.gov/pubmed/21112878.

437. Westerdahl AK, Sutton R, Frykman V. Defibrillator patients should not be denied a peaceful death. Int J Cardiol 2015; 182:440–6. DOI: 10.1016/j.ijcard.2015.01.012. http://www.ncbi.nlm.nih.gov/pubmed/25597981.

438. Willemsen D, Cordes C, Bjarnason-Wehrens B, et al. Rehabilitationsstandards für die Anschlussheilbehandlung und allgemeine Rehabilitation von Patienten mit einem Herzunterstützungssystem (VAD - ventricular assist device). Clin Res Cardiol. Suppl 2016; 11 Suppl 1:2–49. DOI: 10.1007/s11789-015-0077-x. http://www.ncbi.nlm.nih.gov/pubmed/26882905.

439. Brush S, Budge D, Alharethi R, et al. End-of-life decision making and implementation in recipients of a destination left ventricular assist device. J Heart Lung Transplant 2010; 29(12):1337–41. DOI: 10.1016/j.healun.2010.07.001. http://www.ncbi.nlm.nih.gov/pubmed/20817564.

440. Mueller PS, Swetz KM, Freeman MR, et al. Ethical analysis of withdrawing ventricular assist device support. Mayo Clin Proc 2010; 85(9):791–7. DOI: 10.4065/mcp.2010.0113. http://www.ncbi.nlm.nih.gov/pubmed/20584919.

441. Gafford EF, Luckhardt AJ, Swetz KM. Deactivation of a left ventricular assist device at the end of life #269. J Palliat Med 2013; 16(8):980–2. DOI: 10.1089/jpm.2013.9490. http://www.ncbi.nlm.nih.gov/pubmed/23767953.

442. Pitcher D, Soar J, Hogg K, et al. Cardiovascular implanted electronic devices in people towards the end of life, during cardiopulmonary resuscitation and after death: Guidance from the Resuscitation Council (UK), British Cardiovascular Society and National Council for Palliative Care. Heart (British Cardiac Society) 2016; 102 Suppl 7:A1-A17. DOI: 10.1136/heartjnl-2016-309721. http://www.ncbi.nlm.nih.gov/pubmed/27277710.

443. Bundesgerichtshof (BGH). BGH, Urteil vom 25. Juni 2010 - 2 StR 454/09 - LG Fulda. 2010 [cited: 2017-02-24]. http://juris.bundesgerichtshof.de/cgi-bin/rechtsprechung/document.py?Gericht=bgh&Art=en&sid=59e71abacc0d791b04c31d71800b71af&nr=52999&pos=1&anz=2&Blank=1.pdf.

444. Carlsson J, Paul NW, Dann M, et al. The deactivation of implantable cardioverter-defibrillators: Medical, ethical, practical, and legal considerations. Dtsch Arztebl Int 2012; 109(33-34):535–41. DOI: 10.3238/arztebl.2012.0535. http://www.ncbi.nlm.nih.gov/pubmed/23152737.

445. Waltenberger J, Schöne-Seifert B, Friedrich DR, et al. Verantwortlicher Umgang mit ICDs. Der Kardiologe 2017; 11(5):383–97. DOI: 10.1007/s12181-017-0185-6.

446. Padeletti L, Arnar DO, Boncinelli L, et al. EHRA Expert Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy. Europace 2010; 12(10):1480–9. DOI: 10.1093/europace/euq275. http://www.ncbi.nlm.nih.gov/pubmed/20675674.

447. American College of Cardiology (ACC), American Geriatrics Society (AGS), American Academy of Hospice and Palliative Medicine (AAHPM), et al. HRS Expert Consensus Statement on the Management of Cardiovascular Implantable Electronic Devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy. Heart Rhythm 2010; 7(7):1008–26. DOI: 10.1016/j.hrthm.2010.04.033. http://www.ncbi.nlm.nih.gov/pubmed/20471915.

448. Whellan DJ, Goodlin SJ, Dickinson MG, et al. End-of-life care in patients with heart failure. J Card Fail 2014; 20(2):121–34. DOI: 10.1016/j.cardfail.2013.12.003. http://www.ncbi.nlm.nih.gov/pubmed/24556532.

449. Angermann CE, Stork S, Gelbrich G, et al. Mode of action and effects of standardized collaborative disease management on mortality and morbidity in patients with systolic heart failure: The Interdisciplinary Network for Heart Failure (INH) study. Circ Heart Fail 2012; 5(1):25–35. DOI: 10.1161/CIRCHEARTFAILURE.111.962969. http://www.ncbi.nlm.nih.gov/pubmed/21956192.

450. Angermann CE. Comorbidities in Heart Failure: A Key Issue. Eur J Heart Fail 2009; 8(Suppl 1):i5-i10.

451. Zentgraf C. Zum Stand der Versorgungssituation der chronischen Herzinsuffizienz. Eine prospektive Analyse an 1054 konsekutiv rekrutierten Patienten am Interdisziplinären Herzinsuffizienzregister Würzburg. Dissertation zu Erlangung der Doktorwürde der Medizinischen Fakultät der Bayerischen Julius-Maximilians-Universität zu Würzburg. Würzburg: Med. Fakultät der Bayerischen Julius-Maximilians-Universität; 2007.

452. Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003; 42(7):1226–33. http://www.ncbi.nlm.nih.gov/pubmed/14522486.

453. Hobbs FD, Kenkre JE, Roalfe AK, et al. Impact of heart failure and left ventricular systolic dysfunction on quality of life: A cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J 2002; 23(23):1867–76. http://www.ncbi.nlm.nih.gov/pubmed/12445536.

454. Jong P, Vowinckel E, Liu PP, et al. Prognosis and determinants of survival in patients newly hospitalized for heart failure: A population-based study. Arch. Intern. Med 2002; 162(15):1689–94. http://www.ncbi.nlm.nih.gov/pubmed/12153371.

455. Rangaswami J, Bhalla V, Blair JE, et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. Circulation 2019; 139(16):e840-e878. DOI: 10.1161/CIR.0000000000000664. http://www.ncbi.nlm.nih.gov/pubmed/30852913.

456. Kidney Disease: Improving Global Outcomes (KDIGO), Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. 2012 (Kidney inter.; 2 Suppl) [cited: 2018-08-22]. http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO%20AKI%20Guideline.pdf.

457. Kidney Disease: Improving Global Outcomes (KDIGO), CKD Work Group. KDIGO 2012. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. 2013 (Kidney inter.; 3 Suppl) [cited: 2018-05-25]. http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf.

458. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz - Leitlinienreport, 2. Auflage. Version 3. 2017 [cited: 2018-04-23]. DOI: 10.6101/AZQ/000408. http://doi.org/10.6101/AZQ/000408.

459. Redfield MM, Anstrom KJ, Levine JA, et al. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med 2015; 373(24):2314–24. DOI: 10.1056/NEJMoa1510774. http://www.ncbi.nlm.nih.gov/pubmed/26549714.

460. Krum H, Gilbert RE. Demographics and concomitant disorders in heart failure. Lancet 2003; 362(9378):147–58. http://www.ncbi.nlm.nih.gov/pubmed/12867118.

461. Haas SJ, Vos T, Gilbert RE, et al. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 2003; 146(5):848–53. http://www.ncbi.nlm.nih.gov/pubmed/14597934.

462. Ryden L, Armstrong PW, Cleland JG, et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J 2000; 21(23):1967–78. http://www.ncbi.nlm.nih.gov/pubmed/11071803.

463. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for reversible airway disease. Cochrane Database Syst Rev 2002(4):CD002992. DOI: 10.1002/14651858.CD002992. http://www.ncbi.nlm.nih.gov/pubmed/12519582.

464. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005(4):CD003566. DOI: 10.1002/14651858.CD003566.pub2. http://www.ncbi.nlm.nih.gov/pubmed/16235327.

465. Arzt M, Woehrle H, Oldenburg O, et al. Prevalence and Predictors of Sleep-Disordered Breathing in Patients With Stable Chronic Heart Failure: The SchlaHF Registry. JACC. Heart failure 2016; 4(2):116–25. DOI: 10.1016/j.jchf.2015.09.014. http://www.ncbi.nlm.nih.gov/pubmed/26682790.

466. Deutsche Gesellschaft für Schlafforschung und Schlafmedizin (DGSM). S3 Leitlinie Nicht erholsamer Schlaf/Schlafstörung Kapitel „Schlafbezogene Atmungsstörungen bei Erwachsenen“ Version 2.0. S3-Leitlinie. 2017 [cited: 2018-11-09].

467. Bundesärztekammer (BÄK). (Muster-)Kursbuch Psychosomatische Grundversorgung mit integriertem Fortbildungscurriculum „Patientenzentrierte Kommunikation“. 2018 [cited: 2018-10-10]. http://www.bundesaerztekammer.de/fileadmin/user_upload/downloads/pdf-Ordner/Fortbildung/Muster-Kursbuch_PSGV.pdf.

468. Huibers MJ, Beurskens AJ, Bleijenberg G, et al. The effectiveness of psychosocial interventions delivered by general practitioners. Cochrane Database Syst Rev 2003(2):CD003494. DOI: 10.1002/14651858.CD003494. http://www.ncbi.nlm.nih.gov/pubmed/12804471.

469. Mynors-Wallis LM, Gath DH, Lloyd-Thomas AR, et al. Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care. Br Med J 1995; 310(6977):441–5. http://www.ncbi.nlm.nih.gov/pubmed/7873952.

470. Tu R-H, Zeng Z-Y, Zhong G-Q, et al. Effects of exercise training on depression in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials. Eur J Heart Fail 2014; 16(7):749–57. DOI: 10.1002/ejhf.101. http://www.ncbi.nlm.nih.gov/pubmed/24797230.

471. Jeyanantham K, Kotecha D, Thanki D, et al. Effects of cognitive behavioural therapy for depression in heart failure patients: A systematic review and meta-analysis. Heart Fail Rev 2017; 22(6):731–41. DOI: 10.1007/s10741-017-9640-5. http://www.ncbi.nlm.nih.gov/pubmed/28733911.

472. O‘Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure: Results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol 2010; 56(9):692–9. DOI: 10.1016/j.jacc.2010.03.068. http://www.ncbi.nlm.nih.gov/pubmed/20723799.

473. Angermann CE, Gelbrich G, Störk S, et al. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. JAMA 2016; 315(24):2683–93. DOI: 10.1001/jama.2016.7635. http://www.ncbi.nlm.nih.gov/pubmed/27367876.

474. Ekman I, Fagerberg B, Skoog I. The clinical implications of cognitive impairment in elderly patients with chronic heart failure. J Cardiovasc Nurs 2001; 16(1):47–55. http://www.ncbi.nlm.nih.gov/pubmed/11587240.

475. Zuccala G, Pedone C, Cesari M, et al. The effects of cognitive impairment on mortality among hospitalized patients with heart failure. Am J Med 2003; 115(2):97–103. http://www.ncbi.nlm.nih.gov/pubmed/12893394.

476. Vogels RL, Scheltens P, Schroeder-Tanka JM, et al. Cognitive impairment in heart failure: A systematic review of the literature. Eur J Heart Fail 2007; 9(5):440–9. http://www.ncbi.nlm.nih.gov/pubmed/17174152.

477. Ampadu J, Morley JE. Heart failure and cognitive dysfunction. Int J Cardiol 2015; 178:12–23. DOI: 10.1016/j.ijcard.2014.10.087. http://www.ncbi.nlm.nih.gov/pubmed/25464210.

478. Dahrmann B, Sindermann J, Geldmacher T, et al. Lebensqualität und psychisches Befinden von Patienten mit schwerer Herzinsuffizienz mit und ohne apparative Unterstützung der Funktion des linken Ventrikels – eine Querschnittsstudie. Z Psychosom. Med Psychother. 2017; 63(4):388–404. DOI: 10.13109/zptm.2017.63.4.388. http://www.ncbi.nlm.nih.gov/pubmed/29214945.

479. Havakuk O, King KS, Grazette L, et al. Heart Failure-Induced Brain Injury. J Am Coll Cardiol 2017; 69(12):1609–16. DOI: 10.1016/j.jacc.2017.01.022. http://www.ncbi.nlm.nih.gov/pubmed/28335844.

480. Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN), Deutsche Gesellschaft für Neurologie (DGN), Deutsche Alzheimer Gesellschaft – Selbsthilfe Demenz. S3-Leitlinie „Demenzen“, Langversion, Januar 2016, AWMF-Registernummer 038-013. 2016 [cited: 2018-02-06]. http://www.awmf.org/uploads/tx_szleitlinien/038-013l_S3-Demenzen-2016-07.pdf.

481. Triposkiadis F, Giamouzis G, Parissis J, et al. Reframing the association and significance of co-morbidities in heart failure. Eur J Heart Fail 2016; 18(7):744–58. DOI: 10.1002/ejhf.600. http://www.ncbi.nlm.nih.gov/pubmed/27358242.

482. Tang YD, Katz SD. Anemia in chronic heart failure: Prevalence, etiology, clinical correlates, and treatment options. Circulation 2006; 113(20):2454–61. http://www.ncbi.nlm.nih.gov/pubmed/16717164.

483. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29(19):2388–442. http://www.ncbi.nlm.nih.gov/pubmed/18799522.

484. Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013; 368(13):1210–9. DOI: 10.1056/NEJMoa1214865. http://www.ncbi.nlm.nih.gov/pubmed/23473338.

485. Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: An international pooled analysis. Am Heart J 2013; 165(4):575-582.e3. DOI: 10.1016/j.ahj.2013.01.017. http://www.ncbi.nlm.nih.gov/pubmed/23537975.

486. Lewis GD, Malhotra R, Hernandez AF, et al. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. JAMA 2017; 317(19):1958–66. DOI: 10.1001/jama.2017.5427. http://www.ncbi.nlm.nih.gov/pubmed/28510680.

487. Qian C, Wei B, Ding J, et al. The Efficacy and Safety of Iron Supplementation in Patients With Heart Failure and Iron Deficiency: A Systematic Review and Meta-analysis. Can J Cardiol 2016; 32(2):151–9. DOI: 10.1016/j.cjca.2015.06.009. http://www.ncbi.nlm.nih.gov/pubmed/26454467.

488. Anker SD, Kirwan B-A, van Veldhuisen DJ, et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: An individual patient data meta-analysis. Eur J Heart Fail 2018; 20(1):125–33. DOI: 10.1002/ejhf.823. http://www.ncbi.nlm.nih.gov/pubmed/28436136.

489. Jankowska EA, Tkaczyszyn M, Suchocki T, et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: A meta-analysis of randomized controlled trials. Eur J Heart Fail 2016; 18(7):786–95. DOI: 10.1002/ejhf.473. http://www.ncbi.nlm.nih.gov/pubmed/26821594.

490. Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: Systematic review and meta-analysis. Mayo Clin Proc 2015; 90(1):12–23. DOI: 10.1016/j.mayocp.2014.10.007. http://www.ncbi.nlm.nih.gov/pubmed/25572192.

491. Yeo TJ, Yeo PS, Hadi FA, et al. Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF). ESC Heart Fail 2018; 5(2):344–53. DOI: 10.1002/ehf2.12250. http://www.ncbi.nlm.nih.gov/pubmed/29345426.

492. van Veldhuisen DJ, Ponikowski P, van der Meer P, et al. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. Circulation 2017; 136(15):1374–83. DOI: 10.1161/CIRCULATIONAHA.117.027497. http://www.ncbi.nlm.nih.gov/pubmed/28701470.

493. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361(25):2436–48. DOI: 10.1056/NEJMoa0908355. http://www.ncbi.nlm.nih.gov/pubmed/19920054.

494. Bozkurt B, Aguilar D, Deswal A, et al. Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. Circulation 2016; 134(23):e535-e578. DOI: 10.1161/CIR.0000000000000450. http://www.ncbi.nlm.nih.gov/pubmed/27799274.

495. Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ). Verschärfte Empfehlungen bezüglich des Risikos schwerer Überempfindlichkeitsreaktionen auf Eisen-Präparate zur intravenösen Applikation. 2013 (Rote-Hand-Briefe 2013) [cited: 2018-10-09]. http://www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2013/20131021.pdf.

496. Evans WJ, Morley JE, Argilés J, et al. Cachexia: A new definition. Clin Nutr 2008; 27(6):793–9. DOI: 10.1016/j.clnu.2008.06.013. http://www.ncbi.nlm.nih.gov/pubmed/18718696.

497. Valentini L, Volkert D, Schütz T, et al. Leitlinie der Deutschen Gesellschaft für Ernährungsmedizin (DGEM). Aktuel Ernahrungsmed 2013; 38(02):97–111. DOI: 10.1055/s-0032-1332980.

498. Emami A, Saitoh M, Valentova M, et al. Comparison of sarcopenia and cachexia in men with chronic heart failure: Results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). Eur J Heart Fail 2018; 20(11):1580–7. DOI: 10.1002/ejhf.1304. http://www.ncbi.nlm.nih.gov/pubmed/30160804.

499. Vidán MT, Blaya-Novakova V, Sánchez E, et al. Prevalence and prognostic impact of frailty and its components in non-dependent elderly patients with heart failure. Eur J Heart Fail 2016; 18(7):869–75. DOI: 10.1002/ejhf.518. http://www.ncbi.nlm.nih.gov/pubmed/27072307.

500. Ellis G, Gardner M, Tsiachristas A, et al. Comprehensive geriatric assessment for older adults admitted to hospital. Cochrane Database Syst Rev 2017; 9:CD006211. DOI: 10.1002/14651858.CD006211.pub3. http://www.ncbi.nlm.nih.gov/pubmed/28898390.

501. Apóstolo J, Cooke R, Bobrowicz-Campos E, et al. Predicting risk and outcomes for frail older adults: An umbrella review of frailty screening tools. JBI Database System Rev Implement Rep 2017; 15(4):1154–208. DOI: 10.11124/JBISRIR-2016-003018. http://www.ncbi.nlm.nih.gov/pubmed/28398987.

502. Apóstolo J, Cooke R, Bobrowicz-Campos E, et al. Effectiveness of interventions to prevent pre-frailty and frailty progression in older adults: A systematic review. JBI Database System Rev Implement Rep 2018; 16(1):140–232. DOI: 10.11124/JBISRIR-2017-003382. http://www.ncbi.nlm.nih.gov/pubmed/29324562.

503. White WB, Saag KG, Becker MA, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med 2018; 378(13):1200–10. DOI: 10.1056/NEJMoa1710895. http://www.ncbi.nlm.nih.gov/pubmed/29527974.

504. Allen LA, O‘Connor CM. Management of acute decompensated heart failure. CMAJ 2007; 176(6):797–805. http://www.ncbi.nlm.nih.gov/pubmed/17353535.

505. Wakai A, McCabe A, Kidney R, et al. Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev 2013(8):CD005151. DOI: 10.1002/14651858.CD005151.pub2. http://www.ncbi.nlm.nih.gov/pubmed/23922186.

506. Vital FM, Ladeira MT, Atallah AN. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema. Cochrane Database Syst Rev 2013(5):CD005351. DOI: 10.1002/14651858.CD005351.pub3. http://www.ncbi.nlm.nih.gov/pubmed/23728654.

507. Travers B, O‘Loughlin C, Murphy NF, et al. Fluid restriction in the management of decompensated heart failure: No impact on time to clinical stability. J Card Fail 2007; 13(2):128–32. http://www.ncbi.nlm.nih.gov/pubmed/17395053.

508. Blessberger H, Kammler J, Domanovits H, et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity. Cochrane Database Syst Rev 2018; 3(3):CD004476. DOI: 10.1002/14651858.CD004476.pub3. http://www.ncbi.nlm.nih.gov/pubmed/29533470.

509. Bjarnason-Weherns B, Held K, Hoberg E, et al. Deutsche Leitlinie zur Rehabilitation von Patienten mit Herz-Kreislauferkrankungen (DLL-KardReha). Clin Res Cardiol. Suppl 2007; 2(3):1–54.

510. Taylor RS, Walker S, Smart NA, et al. Impact of exercise-based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: An individual patient data meta-analysis of randomised trials. Eur J Heart Fail 2018; 20(12):1735-1743. DOI: 10.1002/ejhf.1311. http://www.ncbi.nlm.nih.gov/pubmed/30255969.

511. Schlitt A, Wischmann P, Wienke A, et al. Rehabilitation in Patients With Coronary Heart Disease: Participation and Its Effect on Prognosis. Dtsch Arztebl Int 2015; 112(31-32):527–34. DOI: 10.3238/arztebl.2015.0527. http://www.ncbi.nlm.nih.gov/pubmed/26334980.

512. Stewart S, MacIntyre K, Hole DJ, et al. More ‚malignant‘ than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001; 3(3):315–22. http://www.ncbi.nlm.nih.gov/pubmed/11378002.

513. Jaarsma T, Beattie JM, Ryder M, et al. Palliative care in heart failure: A position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009; 11(5):433–43. DOI: 10.1093/eurjhf/hfp041. http://www.ncbi.nlm.nih.gov/pubmed/19386813.

514. Ostgathe C, Alt-Epping B, Golla H, et al. Non-cancer patients in specialized palliative care in Germany: What are the problems? Palliative medicine 2011; 25(2):148–52. DOI: 10.1177/0269216310385370. http://www.ncbi.nlm.nih.gov/pubmed/20937612.

515. Leitlinienprogramm Onkologie (OL), Deutsche Krebsgesellschaft (DKG), Deutsche Krebshilfe, et al. Erweiterte S3-Leitlinie Palliativmedizin für Patienten mit einer nicht-heilbaren Krebserkrankung, Langversion 2.0. 2019 [cited: 2019-10-02]. https://www.awmf.org/uploads/tx_szleitlinien/128-001OLl_S3_Palliativmedizin_2019-09.pdf.

516. Bock R de, van den Noortgate N, Piers R. Validation of the Supportive and Palliative Care Indicators Tool in a Geriatric Population. J Palliat Med 2018; 21(2):220–4. DOI: 10.1089/jpm.2017.0205. http://www.ncbi.nlm.nih.gov/pubmed/28792787.

517. Afshar K, Müller-Mundt G, Schneider N. Wie können Patienten mit chronisch fortschreitenden nicht-onkologischen Erkrankungen erkannt werden, bei denen eine Palliativversorgung sinnvoll ist? Z Palliativmed 2016; 17(03):133–8. DOI: 10.1055/s-0042-103176.

518. Afshar K, Feichtner A, Boyd K, et al. Systematic development and adjustment of the German version of the Supportive and Palliative Care Indicators Tool (SPICT-DE). BMC palliative care 2018; 17(1):27. DOI: 10.1186/s12904-018-0283-7. http://www.ncbi.nlm.nih.gov/pubmed/29454343.

519. Gomes B, Calanzani N, Curiale V, et al. Effectiveness and cost-effectiveness of home palliative care services for adults with advanced illness and their caregivers. Cochrane Database Syst Rev 2013(6):CD007760. DOI: 10.1002/14651858.CD007760.pub2. http://www.ncbi.nlm.nih.gov/pubmed/23744578.

520. Rogers JG, Patel CB, Mentz RJ, et al. Palliative Care in Heart Failure: The PAL-HF Randomized, Controlled Clinical Trial. J Am Coll Cardiol 2017; 70(3):331–41. DOI: 10.1016/j.jacc.2017.05.030. http://www.ncbi.nlm.nih.gov/pubmed/28705314.

521. Sidebottom AC, Jorgenson A, Richards H, et al. Inpatient palliative care for patients with acute heart failure: Outcomes from a randomized trial. J Palliat Med 2015; 18(2):134–42. DOI: 10.1089/jpm.2014.0192. http://www.ncbi.nlm.nih.gov/pubmed/25479182.

522. Hoppe JD. Grundsätze der Bundesärztekammer zur ärztlichen Sterbebegleitung. Dtsch Arztebl 2011; 108(7):A-346-8.

523. Alt-Epping B. Klug entscheiden: . in der Palliativmedizin. Vor den Rahmenbedingungen von Endlichkeit und komplexer Belastung sind die Behandlungsziele auf die bestmögliche Symptomlinderung und umfassende Unterstützung zu richten. Dtsch Arztebl 2016; 113(42):A-1870-2.

524. Auerbach AD, Hamel MB, Davis RB, et al. Resource use and survival of patients hospitalized with congestive heart failure: Differences in care by specialty of the attending physician. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Ann Intern Med 2000; 132(3):191–200. http://www.ncbi.nlm.nih.gov/pubmed/10651599.

525. Baker DW, Hayes RP, Massie BM, et al. Variations in family physicians‘ and cardiologists‘ care for patients with heart failure. Am Heart J 1999; 138(5 Pt 1):826–34. http://www.ncbi.nlm.nih.gov/pubmed/10539812.

526. Chin MH, Friedmann PD, Cassel CK, et al. Differences in generalist and specialist physicians‘ knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure. J Gen. Intern Med 1997; 12(9):523–30. http://www.ncbi.nlm.nih.gov/pubmed/9294785.

527. Edep ME, Shah NB, Tateo IM, et al. Differences between primary care physicians and cardiologists in management of congestive heart failure: Relation to practice guidelines. J Am Coll Cardiol 1997; 30(2):518–26. http://www.ncbi.nlm.nih.gov/pubmed/9247527.

528. Philbin EF, Weil HF, Erb TA, et al. Cardiology or primary care for heart failure in the community setting: Process of care and clinical outcomes. Chest 1999; 116(2):346–54. http://www.ncbi.nlm.nih.gov/pubmed/10453861.

529. Reis SE, Holubkov R, Edmundowicz D, et al. Treatment of patients admitted to the hospital with congestive heart failure: Specialty-related disparities in practice patterns and outcomes. J Am Coll Cardiol 1997; 30(3):733–8. http://www.ncbi.nlm.nih.gov/pubmed/9283533.

530. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Asthma - Langfassung, 2. Auflage. Version 5. 2009 [cited: 2018-09-13]. DOI: 10.6101/AZQ/000163. http://doi.org/10.6101/AZQ/000163.

531. Daamen MA, Hamers JP, Gorgels AP, et al. Heart failure in nursing home residents; a cross-sectional study to determine the prevalence and clinical characteristics. BMC Geriatr 2015; 15:167. DOI: 10.1186/s12877-015-0166-1. http://www.ncbi.nlm.nih.gov/pubmed/26675117.

532. Hancock HC, Close H, Mason JM, et al. High prevalence of undetected heart failure in long-term care residents: Findings from the Heart Failure in Care Homes (HFinCH) study. Eur J Heart Fail 2013; 15(2):158–65. DOI: 10.1093/eurjhf/hfs165. http://www.ncbi.nlm.nih.gov/pubmed/23112002.

533. Barents M, van der Horst IC, Voors AA, et al. Prevalence and misdiagnosis of chronic heart failure in nursing home residents: The role of B-type natriuretic peptides. Neth. Heart J 2008; 16(4):123–8. http://www.ncbi.nlm.nih.gov/pubmed/18427636.

534. Allen LA, Hernandez AF, Peterson ED, et al. Discharge to a skilled nursing facility and subsequent clinical outcomes among older patients hospitalized for heart failure. Circ Heart Fail 2011; 4(3):293–300. DOI: 10.1161/CIRCHEARTFAILURE.110.959171. http://www.ncbi.nlm.nih.gov/pubmed/21447803.

535. Boxer RS, Dolansky MA, Frantz MA, et al. The Bridge Project: Improving heart failure care in skilled nursing facilities. J Am Med Dir Assoc 2012; 13(1):83–7. DOI: 10.1016/j.jamda.2011.01.005. http://www.ncbi.nlm.nih.gov/pubmed/21450244.

536. Chen J, Ross JS, Carlson MD, et al. Skilled nursing facility referral and hospital readmission rates after heart failure or myocardial infarction. Am J Med 2012; 125(1):100–9. DOI: 10.1016/j.amjmed.2011.06.011. http://www.ncbi.nlm.nih.gov/pubmed/22195535.

537. Quality of Care and Outcomes Research (QCOR), Heart Failure Society of America (HFSA)Goodlin, S., Dolansky M, et al. Heart failure management in skilled nursing facilities: A scientific statement from the American Heart Association and the Heart Failure Society of America. Circ Heart Fail 2015; 8(3):655–87. DOI: 10.1161/HHF.0000000000000005. http://www.ncbi.nlm.nih.gov/pubmed/25855686.

538. Riley JP, Astin F, Crespo-Leiro MG, et al. Heart Failure Association of the European Society of Cardiology heart failure nurse curriculum. Eur J Heart Fail 2016; 18(7):736–43. DOI: 10.1002/ejhf.568. http://www.ncbi.nlm.nih.gov/pubmed/27220672.

539. Lee VW, Choi LM, Wong WJ, et al. Pharmacist intervention in the prevention of heart failure for high-risk elderly patients in the community. BMC Cardiovasc Disord 2015; 15:178. DOI: 10.1186/s12872-015-0173-3. http://www.ncbi.nlm.nih.gov/pubmed/26702612.

540. Tsuyuki RT, Al Hamarneh YN, Jones CA, et al. The Effectiveness of Pharmacist Interventions on Cardiovascular Risk: The Multicenter Randomized Controlled RxEACH Trial. J Am Coll Cardiol 2016; 67(24):2846–54. DOI: 10.1016/j.jacc.2016.03.528. http://www.ncbi.nlm.nih.gov/pubmed/27058907.

541. Kashour TS, Joury A, Alotaibi AM, et al. Quality of assessment and counselling offered by community pharmacists and medication sale without prescription to patients presenting with acute cardiac symptoms: A simulated client study. Eur J Clin Pharmacol 2016; 72(3):321–8. DOI: 10.1007/s00228-015-1981-1. http://www.ncbi.nlm.nih.gov/pubmed/26592495.

542. Dempsey JT, Matta LS, Carter DM, et al. Assessment of Drug Therapy-Related Issues in an Outpatient Heart Failure Population and the Potential Impact of Pharmacist-Driven Intervention. J Pharm Pract 2016; 30(3):318–23. DOI: 10.1177/0897190016641491. http://www.ncbi.nlm.nih.gov/pubmed/27080398.

543. Roblek T, Deticek A, Leskovar B, et al. Clinical-pharmacist intervention reduces clinically relevant drug-drug interactions in patients with heart failure: A randomized, double-blind, controlled trial. Int J Cardiol 2016; 203:647–52. DOI: 10.1016/j.ijcard.2015.10.206. http://www.ncbi.nlm.nih.gov/pubmed/26580349.

544. Gastelurrutia P, Benrimoj SI, Espejo J, et al. Negative clinical outcomes associated with drug-related problems in heart failure (HF) outpatients: Impact of a pharmacist in a multidisciplinary HF clinic. J Card Fail 2011; 17(3):217–23. DOI: 10.1016/j.cardfail.2010.10.009. http://www.ncbi.nlm.nih.gov/pubmed/21362530.

545. Lowrie R, Johansson L, Forsyth P, et al. Experiences of a community pharmacy service to support adherence and self-management in chronic heart failure. Int J Clin Pharm 2014; 36(1):154–62. DOI: 10.1007/s11096-013-9889-2. http://www.ncbi.nlm.nih.gov/pubmed/24293306.

546. Murray MD, Young J, Hoke S, et al. Pharmacist intervention to improve medication adherence in heart failure: A randomized trial. Ann Intern Med 2007; 146(10):714–25. http://www.ncbi.nlm.nih.gov/pubmed/17502632.

547. Koshman SL, Charrois TL, Simpson SH, et al. Pharmacist care of patients with heart failure: A systematic review of randomized trials. Arch. Intern. Med 2008; 168(7):687–94. DOI: 10.1001/archinte.168.7.687. http://www.ncbi.nlm.nih.gov/pubmed/18413550.

548. Kang JE, Han NY, Oh JM, et al. Pharmacist-involved care for patients with heart failure and acute coronary syndrome: A systematic review with qualitative and quantitative meta-analysis. J Clin Pharm Ther 2016; 41(2):145–57. DOI: 10.1111/jcpt.12367. http://www.ncbi.nlm.nih.gov/pubmed/26954666.

549. Schulz M, Griese-Mammen N, Anker SD, et al. Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: Results of the PHARM-CHF randomized controlled trial. Eur J Heart Fail 2019; 21(8):1012-1021. DOI: 10.1002/ejhf.1503. http://www.ncbi.nlm.nih.gov/pubmed/31129917.

550. Bein T, Bischoff M, Brückner U, et al. Lagerungstherapie und Frühmobilisation zur Prophylaxe oder Therapie von pulmonalen Funktionsstörungen. S2e-Leitlinie. 2015 [cited: 2018-04-20]. http://www.awmf.org/uploads/tx_szleitlinien/001-015l_S2e_Lagerungstherapie_Fr%C3%BChmobilisation_pulmonale_Funktionsst%C3%B6rungen_2015-05.pdf.

551. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz - Leitlinienreport, 2. Auflage. Version 2. 2017 [cited: 2017-09-20]. DOI: 10.6101/AZQ/000391. http://doi.org/10.6101/AZQ/000391.

552. Feltner C, Jones CD, Cene CW, et al. Transitional care interventions to prevent readmissions for persons with heart failure: A systematic review and meta-analysis. Ann Intern Med 2014; 160(11):774–84. DOI: 10.7326/M14-0083. http://www.ncbi.nlm.nih.gov/pubmed/24862840.

553. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Asthma - Langfassung, 3. Auflage. Version 1. 2018 [cited: 2018-09-21]. DOI: 10.6101/AZQ/000400. http://doi.org/10.6101/AZQ/000400.

554. Vedel I, Khanassov V. Transitional Care for Patients With Congestive Heart Failure: A Systematic Review and Meta-Analysis. Ann Fam Med 2015; 13(6):562–71. DOI: 10.1370/afm.1844. http://www.ncbi.nlm.nih.gov/pubmed/26553896.

555. Peters-Klimm F, Campbell S, Hermann K, et al. Case management for patients with chronic systolic heart failure in primary care: The HICMan exploratory randomised controlled trial. Trials 2010; 11:56. DOI: 10.1186/1745-6215-11-56. http://www.ncbi.nlm.nih.gov/pubmed/20478035.

556. Zugck C, Nelles M, Frankenstein L, et al. Telemedizin reduziert bei Patienten mit chronischer Herzinsuffizienz zusätzlich zur optimierten medikamentösen Therapie signifikant die Krankenhausverweildauer. Clin Res Cardiol 2008; 97(1 Suppl):V1734-V1734.

557. Hindricks G, Taborsky M, Glikson M, et al. Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): A randomised controlled trial. Lancet 2014; 384(9943):583–90. DOI: 10.1016/S0140-6736(14)61176-4. http://www.ncbi.nlm.nih.gov/pubmed/25131977.

558. Koehler F, Winkler S, Schieber M, et al. Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: The telemedical interventional monitoring in heart failure study. Circulation 2011; 123(17):1873–80. DOI: 10.1161/CIRCULATIONAHA.111.018473. http://www.ncbi.nlm.nih.gov/pubmed/21444883.

559. Bohm M, Drexler H, Oswald H, et al. Fluid status telemedicine alerts for heart failure: A randomized controlled trial. Eur Heart J 2016; 37(41):3154–63. DOI: 10.1093/eurheartj/ehw099. http://www.ncbi.nlm.nih.gov/pubmed/26984864.

560. Lambrinou E, Kalogirou F, Lamnisos D, et al. Effectiveness of heart failure management programmes with nurse-led discharge planning in reducing re-admissions: A systematic review and meta-analysis. Int J Nurs Stud 2012; 49(5):610–24. DOI: 10.1016/j.ijnurstu.2011.11.002. http://www.ncbi.nlm.nih.gov/pubmed/22196054.

561. Fergenbaum J, Bermingham S, Krahn M, et al. Care in the Home for the Management of Chronic Heart Failure: Systematic Review and Cost-Effectiveness Analysis. J Cardiovasc Nurs 2015; 30(4 Suppl 1):S44-S51. DOI: 10.1097/JCN.0000000000000235. http://www.ncbi.nlm.nih.gov/pubmed/25658188.

562. Bryant-Lukosius D, Carter N, Reid K, et al. The clinical effectiveness and cost-effectiveness of clinical nurse specialist-led hospital to home transitional care: A systematic review. J Eval Clin Pract 2015; 21(5):763–81. DOI: 10.1111/jep.12401. http://www.ncbi.nlm.nih.gov/pubmed/26135524.

563. Driscoll A, Currey J, Tonkin A, et al. Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction. Cochrane Database Syst Rev 2015; 12:CD009889. DOI: 10.1002/14651858.CD009889.pub2. http://www.ncbi.nlm.nih.gov/pubmed/26689943.

564. Koberich S, Lohrmann C, Mittag O, et al. Effects of a hospital-based education programme on self-care behaviour, care dependency and quality of life in patients with heart failure—a randomised controlled trial. J Clin Nurs 2015; 24(11-12):1643–55. DOI: 10.1111/jocn.12766. http://www.ncbi.nlm.nih.gov/pubmed/25661470.

565. Cleland JG, Louis AA, Rigby AS, et al. Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: The Trans-European Network-Home-Care Management System (TEN-HMS) study. J Am Coll Cardiol 2005; 45(10):1654–64. http://www.ncbi.nlm.nih.gov/pubmed/15893183.

566. Freund T, Peters-Klimm F, Boyd CM, et al. Medical Assistant-Based Care Management for High-Risk Patients in Small Primary Care Practices: A Cluster Randomized Clinical Trial. Ann Intern Med 2016; 164(5):323–30. DOI: 10.7326/M14-2403. http://www.ncbi.nlm.nih.gov/pubmed/26833209.

567. Inglis SC, Clark RA, Dierckx R, et al. Structured telephone support or non-invasive telemonitoring for patients with heart failure. Cochrane Database Syst Rev 2015(10):CD007228. DOI: 10.1002/14651858.CD007228.pub3. http://www.ncbi.nlm.nih.gov/pubmed/26517969.

568. Kotb A, Cameron C, Hsieh S, et al. Comparative effectiveness of different forms of telemedicine for individuals with heart failure (HF): A systematic review and network meta-analysis. PLoS. One. 2015; 10(2):e0118681. DOI: 10.1371/journal.pone.0118681. http://www.ncbi.nlm.nih.gov/pubmed/25714962.

569 Flodgren G, Rachas A, Farmer AJ, et al. Interactive telemedicine: Effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2015; 9:CD002098. DOI: 10.1002/14651858.CD002098.pub2. http://www.ncbi.nlm.nih.gov/pubmed/26343551.

570. Kitsiou S, Pare G, Jaana M. Effects of home telemonitoring interventions on patients with chronic heart failure: An overview of systematic reviews. J Med Internet Res 2015; 17(3):e63. DOI: 10.2196/jmir.4174. http://www.ncbi.nlm.nih.gov/pubmed/25768664.

571. Koehler F, Koehler K, Deckwart O, et al. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): A randomised, controlled, parallel-group, unmasked trial. Lancet 2018; 392(10152):1047–57. DOI: 10.1016/S0140-6736(18)31880-4. http://www.ncbi.nlm.nih.gov/pubmed/30153985.

572. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Telemonitoring mithilfe von aktiven kardialen implantierbaren Aggregaten bei ventrikulärer Tachyarrhythmie sowie Herzinsuffizienz. Abschlussbericht. N16-02. Version: 1.2. 2018 (IQWiG-Berichte; 577) [cited: 2019-01-18]. https://www.iqwig.de/download/N16-02_Telemonitoring-mithilfe-von-aktiven-kardialen-implantierbaren-Aggregaten_Abschlussbericht_V1-2.pdf.

573. Luthje L, Vollmann D, Seegers J, et al. A randomized study of remote monitoring and fluid monitoring for the management of patients with implanted cardiac arrhythmia devices. Europace 2015; 17(8):1276–81. DOI: 10.1093/europace/euv039. http://www.ncbi.nlm.nih.gov/pubmed/25983310.

574. Abraham WT, Stevenson LW, Bourge RC, et al. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: Complete follow-up results from the CHAMPION randomised trial. Lancet 2016; 387(10017):453–61. DOI: 10.1016/S0140-6736(15)00723-0. http://www.ncbi.nlm.nih.gov/pubmed/26560249.

575. Minhas AM, Ahmed S, Khan MS, et al. Does Hemodynamic-Guided Heart Failure Management Reduce Hospitalization? A Systematic Review. Cureus. 2017; 9(4):e1161. DOI: 10.7759/cureus.1161. http://www.ncbi.nlm.nih.gov/pubmed/28507833.

576. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22):2117–28. DOI: 10.1056/NEJMoa1504720. http://www.ncbi.nlm.nih.gov/pubmed/26378978

577. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377(7):644–57. DOI: 10.1056/NEJMoa1611925. http://www.ncbi.nlm.nih.gov/pubmed/28507833

578. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. http://www.ncbi.nlm.nih.gov/pubmed/30415602

579. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380(24):2295–306. DOI: 10.1056/NEJMoa1811744. http://www.ncbi.nlm.nih.gov/pubmed/30990260

580. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393(10166):31–9. DOI: 10.1016/S0140-6736(18)32590-X. http://www.ncbi.nlm.nih.gov/pubmed/30424892

581. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). In Erstellung: Nationale VersorgungsLeitlinie Typ-2-Diabetes - Langfassung, 2. Auflage. Geplante Fertigstellung: 2020. https://www.leitlinien.de/nvl/diabetes

582. McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019. DOI: 10.1056/NEJMoa1911303. http://www.ncbi.nlm.nih.gov/pubmed/31535829

583. Petrie MC, Verma S, Docherty KF, et al. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA 2020:[Epub ahead of print]. DOI: 10.1001/jama.2020.1906. http://www.ncbi.nlm.nih.gov/pubmed/32219386

584. Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: Results of the EMPA-REG OUTCOME(R) trial. Eur Heart J 2016; 37(19):1526–34. DOI: 10.1093/eurheartj/ehv728. http://www.ncbi.nlm.nih.gov/pubmed/26819227

585. European Medicines Agency (EMA). Forxiga. dapagliflozin. product information. 11/12/2019 Forxiga - EMEA/H/C/002322 - IG/1171. 2019 [cited: 2020-04-01]. https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_de.pdf.

586. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Datengestütztes, zeitnahes Management in Zusammenarbeit mit einem ärztlichen telemedizinischen Zentrum bei fortgeschrittener Herzinsuffizienz. Rapid Report. Auftrag: N19-01. Version: 1.0. 2019 (IQWiG-Berichte; 822) [cited: 2019-11-21]. https://www.iqwig.de/download/N19-01_Telemonitoring-bei-fortgeschrittener-Herzinsuffizienz_Rapid-Report_V1-0.pdf.

zuletzt verändert: 02.11.2020 11:42